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A medicina regenerativa e a engenharia de tecidos surgiram como alternativas 
para as terapias atualmente usadas no tratamento e substituição de tecidos ou 
órgãos lesados. Estas novas terapias combinam o uso de materiais sintéticos 
ou biológicos ou uma combinação de ambos por forma a produzir um tecido com 
a mesma estrutura e funcionalidade do original, contribuindo para o tratamento 
de tecidos e órgãos lesados. No tecido nativo, as células estão rodeadas por 
uma matriz extracelular que fornece suporte mecânico e biológico às mesmas. 
Hidrogéis são redes poliméricas com elevado conteúdo de água que podem ser 
injetados de uma maneira pouco invasiva, reticulando in situ. As suas 
propriedades mecânicas, físico-químicas e biológicas podem ser ajustadas e 
controladas, fazendo com que estes se tornem fortes candidatos a simular a 
matriz extracelular encontrada in vivo e a fornecer suporte para o crescimento 
celular. O papel do plasma rico em plaquetas (PRP) e dos lisados de plaquetas 
humanas (PL) na fabricação de hidrogéis e também como fonte de fatores de 
crescimento já se encontra descrito. Contudo, os hidrogéis até agora descritos 
apresentam fracas propriedades mecânicas, são degradados rapidamente e 
têm um elevado grau de contração. Assim sendo, o principal objetivo deste 
projeto é a fabricação de um hidrogel a partir de PL, com propriedades 
mecânicas aumentadas e adaptáveis, estáveis in vitro e in vivo. 
PL metacrilatados (PLMA) resultaram da modificação dos PL com anidrido 
metacrílico. Quando expostos à radiação ultravioleta os PLMA são capazes de 
formar hidrogéis por polimerização radicalar. Foram obtidos dois diferentes 
graus de modificação: PLMA100 (baixo grau de modificação) e PLMA300 
(elevado grau de modificação). 
A caracterização mecânica dos hidrogéis mostrou que estes têm propriedades 
mecânicas aumentadas, influenciadas pelo grau de modificação e pela 
concentração de PLMA. Imagens obtidas por microscopia eletrónica de 
varrimento (SEM) demonstraram que o grau de modificação e a concentração 
de PLMA influenciam a porosidade do hidrogel. Baixas concentrações de PLMA 
apresentam poros mais largos do que elevadas concentrações e ainda o 
PLMA300 apresenta uma porosidade bastante apertada. Também foram 
realizados ensaios de libertação de proteína os quais demonstraram uma 
libertação sustentada de proteína por parte do hidrogel.  
Ensaios de cultura celular in vitro foram realizados por forma a avaliar o 
desempenho biológico dos hidrogéis. Células L929 e células estaminais 
adiposas humanas (hASCs) foram encapsuladas no hidrogel e os resultados 
demonstram que a viabilidade celular é mantida durante pelo menos 7 dias. Os 
resultados obtidos para a quantificação de DNA também demonstram que estes 
hidrogéis suportam a proliferação celular.  
Com este trabalho foi possível obter hidrogéis com um elevado conteúdo 
proteico que podem ser usados como plataforma para cultura celular. Na era 
atual, tendo em conta a medicina personalizada e a terapia direcionada, estes 
materiais autólogos poderão ser aplicados na biomedicina, nomeadamente na 
engenharia de tecidos, reduzindo problemas como rejeição de tecidos, resposta 
imune e também problemas éticos. 
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abstract 
 
Regenerative medicine and tissue engineering (TE) are emerging as alternatives 
for the currently used therapies to heal or replace injured tissues and organs. TE 
therapies use synthetic or biological materials or a combination of both in order 
to produce a tissue with the same structure and functionality as the original one 
and this way contribute to tissue healing. In vivo, cells are surrounded by an 
extracellular matrix (ECM) that provides mechanical and biological support for 
cells. Hydrogels are soft and water-rich polymeric networks that can be injected 
in a minimal invasive manner and reticulate in situ. Their mechanical, 
physiochemical and biological properties can be easily tuned, which makes them 
ideal candidates to mimic the ECM and support cell growth. The role of platelet 
rich plasma (PRP) and human platelet lysates (PL) to fabricate hydrogels and as 
a source of growth factors (GFs) has been previously reported. However, the 
materials so far reported, suffer from weak mechanical properties, rapid 
biodegradation and high degree of contraction. Therefore, the main goal of this 
project was the fabrication of a 3D PL hydrogel, with increased and tunable 
mechanical properties and in vitro and in vivo stability. 
Methacryloyl platelet lysates (PLMA) were achieved by modification of PL with 
methacrylic anhydride (MA). PLMA when exposed to UV irradiation are capable 
of forming hydrogels by radicalar polymerization. Two different modifications 
were made: PLMA100 (low-modification degree) and PLMA300 (high-
modification degree).  
Mechanical characterization demonstrate that PLMA hydrogels have increased 
mechanical properties, influenced by PLMA modification degree and also by the 
concentration. Scanning electron microscopy (SEM) images demonstrated the 
influence of modification degree and PLMA concentration in porous network. 
Lower concentration of PLMA showed large porous than higher concentrations 
and PLMA300 showed really tight porous. PLMA protein release assays were 
also performed, demonstrating an overall sustained protein release from the 
hydrogel.  
In vitro cell culture assays were performed in order to evaluate biological 
performance of PLMA hydrogel. L929 cells and human adipose-derived stem cell 
(hASCs) were encapsulated within the hydrogels and for both cell types results 
showed that cell viability is maintained for at least 7 days. DNA quantification 
demonstrated that produced hydrogels support cell proliferation. 
In this work we were capable to obtain hydrogels from a human source with high 
protein content, which can be used as a platform for cell culture. In the current 
era, striving toward personalized medicine and targeted therapy, these type of 
autologous materials will certainly find applications in biomedical applications, 
namely tissue engineering strategies, reducing problems like tissue rejection, 
immune response and also reduces ethical and regulatory issues. 
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1. Background 
Abstract 
Tissue engineering (TE) is one of the most exciting interdisciplinary and 
multidisciplinary research areas and is growing exponentially over time. Although 
considerable progress has been made, the development of a biomaterial that recapitulate the 
complex human biological microenvironment found in vivo is still a challenge. Also, there 
is an increasing interest in the use of autologous approaches in TE strategies.  
Recognizing the unprecedented potential of the platelet-rich plasma (PRP)/human 
platelet lysates (PL) based materials to support three-dimensional (3D) cell culture and 
considering their actual limitations, such as poor mechanical stability this project aims to 
develop a robust PRP/PL based hydrogel for applications in TE. This will be made by the 
chemical modification of proteins present in the PRP/PL to enhance its chemical reactivity 
towards a range of reactive monomers and the method to prepare de PRP derived 3D matrix. 
Benefits will come from the possibility of modelling individualized therapies, the use of 
autologous approaches is highly required, as it avoids the problem of tissue rejection, 
immune response and also reduces ethical and regulatory issues. Platelets are unique blood 
elements involved in healing processes and play a considerable role in tissue regenerative 
processes. Therefore, the potential of human PL based materials is huge.  
1.1. Tissue engineering and Regenerative medicine 
TE is one of the major areas of regenerative medicine. It is defined as an 
interdisciplinary field that encompasses biological science and engineering areas applied to 
the principles of cell transplantation, materials science, and engineering towards the 
development of biological substitutes that can restore and maintain normal tissue function1,2. 
Human body has the capacity to remodel and regenerate small defects, however, when severe 
injuries or large defects occur it is harder or even impossible to heal on its own, thus the 
importance of TE and regenerative medicine3. Currently, therapies based on organ and tissue 
transplantation are widely used as a solution to heal or replace injured tissues and organs but 
there are still many limitations in this strategy, such as lack of donors, which leads to patient 
death while waiting for donor organs, and severe immune complications. Considering that, 
TE may be the answer to bypass these obstacles1,4. 
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TE therapies involve numerous strategies like the use of synthetic and biological 
materials, cells and the combination of both to replace structurally and functionally the 
missing tissue or to contribute to tissue healing1. These TE strategies are usually divided into 
categories4,5: 
 direct injection of cells into the tissue of interest or the systematic circulation  
 cells implantation after they have been combined to form a 3D tissue structure 
 scaffold-based delivery of molecules such as drugs, proteins and 
oligonucleotides. 
 direct delivery of molecules. 
TE scaffolds can be synthetic or natural based. Synthetic scaffolds are widely used 
in TE applications, as the material mechanical properties can be precisely controlled. On the 
other hand, natural based materials can provide a large variety of biofunctional motifs that 
regulate cell adhesion and proliferation processes and cell phenotype. So, the ideal scaffold 
must combine the easily tunable mechanical properties of the synthetic materials, provide 
biofunctionality of natural based materials6 and must also facilitate effective nutrient 
transfer, gas exchange and metabolic waste removal7. 
Extracellular matrix (ECM) is a dynamic structure which provides not only essential 
physical support for the cellular constituents but also contributes to biochemical signaling, 
required for tissue morphogenesis, differentiation and homeostasis. ECM is composed  of 
glycosaminoglycans and fibrous proteins like collagen, elastin, fibronectin and laminin and 
is constantly remodeled by cells during development, homeostasis and wound healing3,7,8. 
Therefore, for TE applications, design and engineer a culture microenvironment that can 
mimic the native tissue and its ECM, its soluble bioactive factors and products of cell-cell 
interactions is desirable so they can replicate tissue functions in vitro3,7. However this is a 
huge challenge due to the ECM heterogeneity and complexity7.  
Over the past two decades there has been an emergence of the TE industry. Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) are the responsible 
entities to approve all the products involved in these areas. However, this is a difficult 
process because it is time consuming and requires high monetary investment. Approval of 
drugs or biological products requires many years of development and testing, involving 
several phases. The efficacy of regenerative medicine and TE products has been increasing 
and a significant number of products and therapies have received FDA approval and are now 
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commercially available. For example, the first FDA-approved biologic product for 
orthopedic applications uses autologous chondrocytes which are harvested, expanded ex vivo 
and implanted in the patient at the site of injury1. 
A reasonable number of conditions have to be taken into account for the advancement 
and effective clinical application of regenerative medicine and TE therapies. First, isolated 
stem cells often require the creation of modulated microenvironments that provide specific 
cues for a tight control over cell behavior, which will lead to efficacy after transplantation 
and increase their safety profile. Second, most engineered tissues need vascularization for 
survival and function and thirdly, creating a pro-regeneration environment within the patient 
may dramatically improve outcomes of regenerative medicine strategies in general1. 
1.2. Cell culture platforms  
Culturing cells and tissues in vitro in two-dimensional (2D) substrates is still the most 
used platform for in vitro cell culture, however 2D substrates can’t mimic cell growth in 
vivo. In 2D cultures, only a segment of the cell membrane can interact with the ECM and 
neighboring cells (Figure I.1A), while the rest of the cell is exposed to the culture medium. 
This affect the intracellular signaling, phenotypic fate and interactions with soluble factors8. 
Abnormal cell morphology characteristic of 2D cell culture influences many cellular 
processes like cell proliferation and differentiation, apoptosis and gene and protein 
expression9. Cells also experience the homogeneous concentration of nutrients, growth 
factors (GFs) and cytokines present in the culture medium with the section of membrane that 
contacts the surrounding medium, while in vivo the entire cell membrane is in contact with 
the medium8. 2D cell culture limits cells to a planar environment and restricts the more 
complex morphologies observed in vivo and, as a result, 2D substrates cultured cells will not 
reflect the situation in vivo, where cells grow within a complex 3D microenvironment8,9. 3D 
cell cultures platforms have been introduced in order to better mimic mechanical and 
biochemical signals present in native ECM, providing more physiologically relevant 
information and more predictive data for in vivo tests (Figure I.1B-D)7. Table I.1 shows a 
comparison of cell/tissue behavior under 2D and 3D cell culture conditions. 
Recently, an effort has been made in order to develop a variety of 3D cell culture 
platforms, to be applied in drug discovery, cancer cell biology, stem cell study, engineered 
functional tissues for implantation and other cell-based analysis9.  
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Figure I.1.  Schematic representation of a 2D cell culture model (A) and typical 3D cell culture systems: cell 
growing on matrix surface in contact with culture media (B) and cells embedded within the matrix (C) and 
submerged in culture media. 
Over the past few decades, researchers have explored new materials for cell culture 
within a 3D matrix, overcoming some of the limitations posed by 2D cell culture systems. 
3D cell culture strategies include the combined use of cells and 3D porous scaffold materials 
serving as structural support for cells. To this end, cells have to be seeded or encapsulated 
in the 3D matrix. However, there are still some challenges associated with the use of 3D 
scaffolds. First, the oxygen diffusion within the scaffold requires special notice. Also, 
regulation of nutrients distribution and metabolites diffusion is an important issue because 
cellular differentiation and tissue homeostasis will be influenced by its availability. Finally, 
considering in vitro assays, working with 3D networks, cells have limited accessibility for 
immunostaining, also it may difficult access and extract secreted proteins, DNA or RNA 
from the cells8.  
Feature/Function 2D culture 3D culture 
Tissue-specific architecture Poor Rich 
Cell morphology Flat, extended Round, contracted 
Interactions Limited Multiple 
Cell motility Fast, free Slow, restricted 
Cell adhesion Weak Strong 
Cell growth Directional All directions 
Cell proliferation High Low 
Apoptosis Induced Tissue-like 
Intracellular stiffness Higher in 3D 
Cell polarization Partly Full 
Extracellular matrix remodeling Absent or poor Present 
Fluid perfusion 1D 3D 
Signaling and diffusion Asymmetric Nearly symmetric 
Metabolic rate High Low 
 
Table I.1. Comparison of cell/tissue behavior under 2D/3D culture conditions (adapted from H. Geckil et al, 
2010). 
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In this change from de 2D cell cultures to the 3D cell cultures, hydrogel-based 
approaches have been widely explored for several biomedical applications10. Great efforts 
have been made in order to demonstrate the usefulness and potential of hydrogels as 
scaffolds for TE and as drug carriers3. In fact, the 3D culture approach is likely to result in 
many commercial success stories for the key players and several stakeholders in the foreseen 
future. 
1.3. Hydrogels in Tissue Engineering and Regenerative Medicine 
The interest in hydrogels for biomedical applications started around 1990s, partly 
because of emergence of the TE field. Since discovery of hydrogels as a good way to mimic 
native extracellular matrix (ECM), they have been the target of many studies7. Hydrogels 
are soft 3D crosslinked insoluble hydrophilic network systems with high water content, that 
allow for an easy transport of oxygen, nutrients and cell metabolites. Hydrogels have 
received particular attention because of their structural and compositional similarities with 
ECM and extensive framework for cellular proliferation and survival7,8,11,12.  
In vitro applications of hydrogels are based on the idea that they can work as  model 
systems for: a) drug delivery – the porous structure of hydrogel enables the introduction of 
a relatively large load of drugs and drug release kinetics can be controlled by controlling 
hydrogel mechanical, physical and chemical properties; b) diagnostics – hydrogels could be 
utilized as components of integrated sensors within microdevices providing a better 
understanding of disease and organ failure caused by agents such as chemical toxins, 
bacterial and viral pathogens by cell-based chem-bio sensing; c) cell encapsulation and cell 
culture – the similarities to the ECM composition has proven to be a valuable tool to provide 
a structure inside where cells can spread and proliferate7.  
In particular, hydrogels designed for cell encapsulation have to be capable of13: 
 suffer gelation without damaging cells; 
 be nontoxic to the cells and surrounding tissues after gelation; 
 provide appropriate diffusion of nutrients and metabolites to and from the 
encapsulated cells; 
 have sufficient mechanical integrity and strength to resist to in vitro and in in 
vivo implantation; 
 in vivo degradation with non-toxic degradation by-products. 
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Variations on the stiffness of the hydrogel are related with changes of the cell 
morphology, metabolic activity and proliferations rate12. Physicochemical properties of the 
hydrogels depends on the monomers and macromers used, synthesis and fabrication 
methods, solvent conditions, degradation and mechanical loading history11,14. The major 
physicochemical parameters that determined the properties of a hydrogel are resumed in 
figure I.2. Adequate mechanical performance of hydrogels depends on specifying, 
characterizing and controlling mechanical properties of the material like elasticity, 
viscoelastic behavior, tensile strength and failure strain. These properties are not only 
affected by polymer and crosslinker characteristics, but also by gelation conditions, gel 
swelling and degradation13. Swelling properties of hydrogels are also important in many 
applications because it affects some parameters like solute diffusion, surface and mechanical 
properties and surface mobility. The pore size of the network and interaction between the 
polymer and the solvent are characteristics that influence the degree of swelling15.  
It is also important to understand and control the degradation rate of hydrogels. There 
are three mechanisms by which hydrogel degradation occurs: hydrolysis, enzymatic 
cleavage and dissolution. Hydrolysis occurs normally in synthetic hydrogels at a constant 
rate in vivo and in vitro and can be manipulated by the composition of the material. 
Enzymatic degradation occurs depending on the cleavage sites in the polymer and the 
amount of available enzymes in the scaffold environment. The dissolution process of 
degradation depends on the ionic environment in which the ionically crosslinked scaffold is 
placed13.  
Hydrogels can be classified into natural, synthetic and semi-synthetic according to 
their source. Synthetic hydrogels can be formed from poly(ethyleneglycol), poly(lactic acid), 
poly(glycolic acid), poly(lactic-glycolic acid), poly(vinyl alcohol), poly(2-hydroxyethyl 
methacrylate) among other. Natural based polymers include agarose, alginate, chitosan, 
hyaluronan, fibrin, collagen, chondroitin sulfate7,11, laminarin16, gelatin17 or matrigel among 
others. Recently, engineered hybrid hydrogels (combining both types of polymers) have 
been increasingly reported11. In case of using synthetic polymers, they are generally 
designed to be nontoxic to the cells and to the surrounding tissue, do not activating a chronic 
immune response13. Hydrogels based on natural biopolymers have potential advantages over 
synthetic polymers, such as excellent biocompatibility, possible bioactive motifs encoded in 
their chemical structures18 and they have similar properties of native ECM. However, the 
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inherent variability due to their biological origin and possible immunoresponse makes 
natural hydrogels more difficult to work with from a clinical viewpoint19. 
 
Figure I.2. Schematic representation of the parameters that influence some properties of polymeric hydrogels. 
The polymer concentration, molecular weight and chemical composition directly influence gelation process, 
fabrication time, shear stress and network properties. These properties will influence cell viability, proliferation 
and differentiation. 
 
The great biological performance of some materials such as collagen or Matrigel  
as a cell-culture substrate and in angiogenesis assays makes them a gold standard for cell 
culturing.  Although the great biological response in terms of cell adhesion and 
proliferation there are important concerns related to their animal origin and difficult 
manipulation. Researchers have been looking for alternatives to overcome certain 
limitations of Matrigel and collagen. Some works rely on the use of synthetic inert 
materials that may be further functionalized with specific bioactive domains while others 
focus on the use of human derived materials. Despite the design flexibility for specific 
applications, synthetic systems are typically expensive and their synthesis can be time 
consuming, requiring often multiple processing steps. In the current era, striving toward 
personalized medicine and targeted therapy, the development of materials that mostly 
mimics the in vivo environment is one of the most important topics to address20,21.  The 
aim of this project is the development of biological relevant materials that could be used 
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as an enabling platform for personalized tissue engineering or drug discovery. This will 
be performed using human platelet rich plasma as raw material to produce the hydrogels. 
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Abstract  
Platelet-rich plasma (PRP) and its derivatives have been widely investigated and 
applied in regenerative medicine. The use of PRP as a supplement of cell culture media has 
consistently shown to potentiate stem cell proliferation, migration, and differentiation. In 
addition, the clinical utility of PRP is supported by evidence that PRP contains high 
concentrations of growth factors (GFs) and proteins which contribute to the regenerative 
process. PRP based therapies are cost effective and also benefit from the accessibility and 
safety of using the patient's own GFs. In the last years, it has been witnessed a great 
development on PRP based biomaterials, with both structural and functional purposes. 
Herein, we overview the most relevant PRP applications encompassing PRP based materials 
for tissue engineering and regenerative medicine. This review also summarizes the 
challenges in the field and provides a perspective on future directions in this field.  
1. Platelets 
Platelets are a natural reservoir of multiple proteins and growth factors (GFs) stored 
in the α-granules. In vivo, platelets are activated at sites of tissue injury, where they promote 
tissue repair, including revascularization. Therefore, through lysis of human platelets, GFs 
can be extracted, providing a less expensive and safer alternative to the use of recombinant 
or animal proteins and GFs. For decades, platelet concentrates have been a standard 
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transfusion component for the treatment of clotting disorders1. The platelet concentrates are 
transfused to the patients who suffer from thrombocytopenia or some other platelet disorder 
in order to sustain the hemostatic function. The use of platelets has been increasing in the 
last 30 years, due to advanced surgical techniques and therapies. Nowadays, they are 
considered vital products in blood banking2,3.  
Platelets are not only involved in maintenance of human body but also play an 
important role in the coagulation and healing processes2,3. When activated (figure II.1) by 
substances such as thrombin, calcium chloride or collagen4, they release some molecules 
present in the α-granules, including GFs and multiple cytokines. Such molecules, when in 
contact with cell transmembrane receptors promote expression of genes involved  in 
processes like cellular recruitment, growth and morphogenesis3. Dense granules contain 
serotonin, histamine, dopamine, calcium and adenosine. Serotonin and histamine, when 
released, increase capillary permeability recruiting inflammatory cells to the site of injury 
and adenosine binds to its receptor in order to modulate inflammation during wound healing. 
Dopamine works as a regulator of heart rate and blood pressure and calcium is a cofactor for 
platelet aggregation2.  
 
Figure II.1. Platelet activation process. Substances like thrombin, calcium chloride and collagen can activate 
platelets. Activated platelets release some molecules like cytokines or growth factors that are involved on 
cellular recruitment, growth and morphogenesis. 
 
Platelet-rich plasma (PRP) is an autologous source of platelets. In PRP the normal 
concentration of platelets is at least 1x106 platelets/μL in 5 mL of plasma, while in whole 
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blood range from 1,5x105 platelets/μL to 3,5x105 platelets/μL2,5. PRP, as a “cocktail” of 
multiple GFs, may be used in vitro to better mimic of what happens in vivo. First reports on 
the use of PRP as a possible therapy are from 1990s, with its application in cardiac surgery6 
and also in bone grafts7. Nowadays, there are several areas where the potential therapeutic 
effect of PRP is documented: dentistry7–13, orthopedics3,14,15, neurology16,17, plastic 
surgery18, musculoskeletal conditions19 and also in vitro fertilization20. 
2.  Preparation of platelet-rich plasma and platelet lysates 
PRP is obtained from whole blood samples by a differential centrifugation process 
(Figure II.2). Only two spins are used: after the first spin (high speed) two layers are obtained  
– one is platelet poor plasma (PPP) and the second one is the mixture of red blood cells and 
PRP; after a second spin of 10 minutes (low speed) three layers are obtained – one is PPP, 
the second one is PRP and the third are red blood cells4,21,22.  
Human platelet lysates (PL) are obtained from platelets present in PRP. PRP is 
treated with  freeze/thaw cycles for platelets disruption and release of their content (e.g. 
proteins, GFs and cytokines)23 (Figure II.2). Standardized freeze/thaw cycles of -80ºC and 
37ºC have been widely used for the PL preparation. Nevertheless, recent study suggests 
−196°C/4°C cycles for increased concentration of GFs24. Additionally, there are other 
processes described in the literature for the preparation of PL such as calcium chloride and 
thrombin activation, still freeze/thaw technique appears to be more effective5.  
3. Biochemical composition of platelet-rich plasma 
GFs present in human PRP include platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF)25, insulin-like growth 
factor I and II (IGFI and II),  transforming growth factor β (TGF-β)26, epidermal growth 
factor (EGF), epithelial cell growth factor (ECGF)27, connective tissue growth factor 
(CTGF), platelet factor 4 (PF4), interleukin 8 (IL-8) and keratinocytes growth factor 
(KGF)28. These GFs perform functions such as chemoattraction, cell proliferation and 
maturation, matrix synthesis and angiogenesis2,4.  
Some of these factors are also present in PL such as PDGF, TGF- β, IGF, FGF, EGF, 
VEGF and ECGF2. Other components present in PL are fibrinogen that plays an important 
role in blood clotting cascade and fibronectin that affects cell adhesion, growth, migration 
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and differentiation2,4. Also clotting factors are present – factor V and Va, factor XI, protein 
S and antithrombin – and all of them are responsible for thrombin activation and fibrin clot 
formation2. 
 
Figure II.2. Schematic representation of PRP isolation and PL preparation by freezing and defrosting 
technique. 
4. Human platelet-rich plasma as an alternative for animal-derived 
serum 
Traditional protocols for the isolation and in vitro culture of cells commonly involve 
culture media supplemented with fetal bovine serum (FBS).  The search for alternatives to 
the use of FBS in in vitro cell culture has become a major goal in terms of Good 
Manufacturing Practice (GMP), to ensure animal product-free conditions. There are also the 
ethical issues associated with the collection methods of animal serums and potential limits 
of availability29,30. For clinical-scale manufacturing, serum-free and xenogeneic-free 
formulations have also been suggested as alternatives to FBS-supplemented media. PL has 
been suggested as an efficient alternative to FBS for cell and tissue expansion, reducing the 
risks of transmission of xenogeneic contaminants as virus, bacteria and prions, as well as 
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xenogeneic antigens. Increased safety for cell therapy protocols and cost reduction are the 
major benefits of human alternatives when compared to animal-derived mediums or 
mixtures of recombinant GFs31. The influence of different supplements for in vitro cell 
culture was studied by V. Mirabet et al where they conclude that cell-based therapies can 
benefit if products from human origin like PL are used as they can avoid the risk of 
xenogeneic infections32. 
 
Table II.1. GFs, cytokines and chemokines present in PRP and GFs, cytokines/chemokines, adhesive proteins 
and clotting factors present in human platelet α-granules1,2,28,39,40. 
 
 
Molecule 
Category 
Molecule Biologic Activity 
PRP 
Growth 
Factors 
TGF-β1, bFGF, 
PDGF-A and B, 
PD-EGF, VEGF, 
ECGF, IGF-I and II 
CTGF and KGF  
Matrix synthesis, chemoattraction, 
cell proliferation and maturation, 
increase angiogenesis and vessel 
permeability, mitogenesis regulation, 
collagen synthesis and collagenase 
secretion regulation, fibrosis, platelet 
adhesion, pro-inflammatory 
mediation     
Cytokines 
and 
chemokines 
PF4 and IL-8 
Chemoattraction, cell recruitment, 
pro-inflammatory mediators 
Human 
platelet α-
granules 
Growth 
Factors 
TGF-β1 and 2, 
PDGF, IGF-I and 
II, bFGF and FGF-
2, EGF, VEGF-A 
and C, HGF and 
ECGF 
Matrix synthesis, chemoattraction, 
cell proliferation, differentiation and 
maturation, angiogenesis 
Cytokines 
and 
chemokines 
RANTES, IL-8, 
MIP-1α, GRO-α, 
ENA-78, MCP-1, 2 
and 3, IL-1β, 
CXCL6, SDF-1α, 
PF4, neutrophile 
chemo active 
protein 
Chemotaxis, cell proliferation and 
differentiation 
Adhesive 
proteins 
Fibrinogen Blood clotting cascade 
Fibronectin 
Affects cell adhesion, growth, 
migration and differentiation 
Clotting 
factors 
Factor V/Va, XI, 
protein S and 
antithrombin 
Thrombin activation and fibrin clot 
formation 
19 
 
Studies with different cell types have shown that cells cultured in vitro with PL as 
medium supplement proliferate better when compared with cultures using FBS as a 
supplement. Cells from bone marrow32, adipose tissue32,33, trabecular bone32, dental pulp32, 
mesenchymal stem cells34,35, human articular chondrocytes33, myofibroblasts36, human 
immortal keratinocyte cell line37 and osteoblasts38 respond to the use of PL with increased 
proliferation rate. It was also reported that the use of PL instead of FBS may have an 
influence in cell morphology. For example, when osteoblasts, cartilage cells, bone marrow 
cells and mesenchymal stem cells are cultured with PL, cell morphology is affected possibly 
due to the higher proliferation rate32,35,38. Apparently, this do not interfere with the 
differentiation potential and immunophenotypic characteristics, at least in case of 
mesenchymal stem cells31.  
The proliferation process is influenced by the presence of cytokines, GFs and 
attachment factors. These molecules are responsible for cellular migration, redistribution, 
adhesion and proliferation and they are present in PL. This is a reason why cells show higher 
proliferation rates when PL are used as a supplement in culture media21. PL have a total 
protein content typically exceeding 50-55 mg/mL while for example FBS composition 
include low and high molecular weight proteins and protein content is on average 38 mg/mL.  
Despite the promising results, a major concern regarding the use of PRP is their 
heterogeneity and demanding characterization. Advanced characterization techniques such 
as mass spectrometry and two-dimensional gel electrophoresis analyses could be important 
for a better characterization and standardization in the use of PL29.  
5. Platelet-rich plasma and fibrin based materials 
Liquid PRP contains fibrinogen, which is transformed in a fibrin matrix by thrombin 
cleavage (figure II.3). In vivo, fibrin acts as a scaffold for tissue repair and provides important 
cues for directing cell phenotype following injury. This matrix can be broken down by 
plasmin enzyme through a process called fibrinolysis41. Based on this phenomena, 
researches have been exploring fibrin gel preparation in vitro by the addition of thrombin 
and calcium to PRP/PL. One of the first commercial applications of fibrin gels was in the 
development of fibrin sealants. This type of sealants are available in Europe since 1972, and 
in the last years a number of novel fibrin sealants have been approved by the Food and Drug 
Administration for use as haemostats in surgery and adhesives for skin graft attachment42.  
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Fibrin matrix forms aligned fibrils in direction of extension and perpendicular to the 
direction of compression, with mechanical properties suitable for vascular tissue 
engineering43. J. N. Long and R. T. Tranquillo developed materials with organized elastic 
fibers formed when neonatal rat smooth muscle cells were cultured in fibrin gels44. Their 
findings suggest that fibrin-based constructs can be used as a model system for the study of 
three-dimensional (3D) elastic structures. The combination of fibrin gels with hyaluronic 
acid was proposed by T. N. Snyder et al as a suitable 3D environment for the proliferation 
of bone marrow-derived mesenchymal stem cells45. Recently, Marcinczyk et al proposed 
fibrin based gels supplemented with laminin as tissue engineered constructs for skeletal 
muscle regeneration46.  
 
Figure II.3. Fibrin clot formation process. In response to a tissue wound (A) platelets start to aggregate at the 
injury site (B). Coagulation cascade is activated and fibrinogen is transformed in fibrin by thrombin cleavage 
(C). The end of the process is a fibrin clot formation (D). 
 
As previously referred in this review, PL based gels are usually formed by the 
addition of calcium and thrombin that triggers a coagulation cascade, promoting fibrinogen 
polymerization into fibrin clots. G. Walenda et al reported a PL based gel that provides a 3D 
scaffold for mesenchymal stromal cells expansion by addition of calcium ions to PL26. T. M. 
Fortunato et al47 and S. T. Robinson et al48 described the fabrication of PL gels and reported 
that PL based gels have the capacity to efficiently release GFs essential at promoting cell 
adhesion and proliferation. They also demonstrate that these gels support the formation of 
fully human capillary network, establishing a de novo endothelial network and lumen present 
in cappilaries47, and led to a rapid neovascularization of ischemic tissues48. The results from 
these works reveal that PL gels have unique structural properties that allow it to behave as a 
viscoelastic solid with improved mechanical properties compared to fibrin only hydrogels. 
Furthermore,  mechanical measurements have shown that PL gels can have a very soft and 
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viscous consistency with increasing elasticity with the increase of PL percentage26. Despite 
all the great intrinsic properties of PL based gels, this type of materials have poor mechanical 
properties and poor stability in vivo and cell culture conditions49. The development of new 
crosslinking methods is therefore a need. Considering this, P. Babo et al reported the 
fabrication of PL-based membranes by crosslinking PL proteins with genipin27. These 
membranes show particularly high stiffness and elasticity, important characteristics for 
regeneration of soft tissues, and a long-term stability, which is an uncommon characteristic 
of PL based biomaterials. The authors also demonstrated the potential of these membranes 
to act as a substrate for stem cell attachment and growth and to provide a propitious 
environment to cells development because of its richness in GFs. From these membranes, P. 
Babo et al made multipatterned devices with six different patterns and studied periodontal 
ligament cells proliferation, migration and alignment50.  This technique was shown to be an 
effective strategy for improvement of periodontal regeneration tissue, as they promote the 
proliferation of periodontal ligament cells. 
6. Hybrid platelet-rich plasma based materials 
PRP and PL have been combined with different biopolymers not only to improve the 
mechanical properties of PRP/PL based materials but also to render the biopolymers 
bioactive and mimic native extracellular matrix or for the controlled delivery of GFs. This 
may represent important biological and economic advantages51,52, as recombinant GFs 
widely used are very expensive and may promote immunogenic reactions52,53. Methods to 
create 3D matrices with incorporated PL include incubation of the polymeric matrices with 
PL solutions or mixing PL with the polymeric precursor before curing21,54. 
For many applications there is a need for chemically crosslinked or hardened 
biomaterials. Since most of the natural based polymers do not crosslink in a stable structure 
at body temperature, it is necessary to stabilize these materials by establishing chemical 
crosslinks between the polymer chains. Chemical crosslinking typically relies in reagents 
such as genipin, glutaraldehyde or carbodiimides. The incorporation of moieties that allow 
for photoinduced crosslinking, is also attractive and have been widely explored in the 
synthesis of materials for biomedical applications.55–57. This type of modification results in 
materials that are easily crosslinked by light irradiation avoiding the use of toxic 
components, with tunable mechanical properties and stable at cell culture conditions and in 
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vivo. For example, X. Liu et al developed an in situ photocrosslinkable PRP – complexed 
hydrogel glue by combination of a photoresponsive hyaluronic acid group with PRP58. 
Results showed that it is a robust hydrogel scaffold that provides a controlled release of GFs 
and strong tissue adhesive ability. In vivo tests demonstrated that this PRP derived hydrogel 
can promote hyaline cartilage regeneration. Controlled release of GFs is an important 
characteristic of PRP/PL biomaterials as this property increases therapeutic efficacy of these 
materials.  
R. Ito et al  proposed a collagen/gelatin scaffold impregnated with PL which 
accelerates formation of dermis-like tissue in mice59. Their findings also indicate that 
collagen/gelatin scaffold bind to TGF-β and PDGF-BB and release these GFs in a sustained 
manner. V. E. Santo et al, have shown that, the incorporation of PL in gellan gum gels 
significantly improved cellular adhesion and viability in the 3D constructs25. The use of 
microfluidic tools allowed the design of a fiber-like hydrogel incorporating a gradient of PL 
along the length of the fiber. A hydrogel based on PL loaded chitosan-chondroitin sulfate 
nanoparticles was also developed by the same authors60. Biological assays showed that the 
hydrogels maintained cell viability and that PL can work as a GFs supplement for cell 
proliferation. The use of PL to build these aggregates can also provide mechanical stability 
to the 3D constructs. Such type of results strengthen the potential of using PRP/PL in order 
to provide bioactive signals could enhance a therapeutic effect but could be also a structural 
element in the development of biomaterials.  
Several works reported on the influence of PL in proliferation, growth and 
differentiation of many cell types, including mesenchymal stem cells, adipose derived stem 
cells or endothelial cells. For example, J. Leotot et al studied how PL can influence 
mesenchymal stromal cells behavior if used as a coating of hydroxyapatite/β-tricalcium 
phosphate scaffolds61. Not only a higher number of mesenchymal stromal cells adhered to 
the scaffold but also cells had increased cytoplasmic extensions after 3 hours in culture. After 
24 hours in culture, cells showed an elongated shape covering almost entirely the scaffold 
and 7 days later mesenchymal stromal cells completely covered the biomaterial. 
Proliferation and differentiation of adipose derived stem cells (hASCs) are also influenced 
by the presence of PL. S. Oliveira et al have shown that PL and marine-origin 
polysaccharides assembled by layer-by-layer and shaped into fibrils by freeze-drying over 
3D scaffolds induced hASCs differentiation into mature osteoblasts52. They also observed 
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that the fibrillar structures with PL allowed a 3D organization of the mineralization. This 
type of hierarchal scaffolds combined with PL demonstrated also pro-angiogenic properties, 
promoting formation of tubular structures in endothelial cells62. L. S. M. Teixeira et al 
studied the incorporation of PL in dextran-tyramine hydrogels to provide chemo-attractant 
properties and trigger chondrogenic differentiation of mesenchymal stromal cells63. Their 
results suggest that dextran hydrogels complemented with PL can potentially be used as a 
cell-free approach to repair cartilage defects. Using a more selective strategy C. A. Custódio 
et al reported the synthesis of chitosan microparticles functionalized with PL derived GFs64. 
The functional particles assembled into a stable 3D construct triggered by the presence of 
hASCs, which act as binder agents and induce the formation of a hydrogel network.  
Overall, the incorporation or blending of PRP/PL in biomaterials may be a key way 
to increase the therapeutic efficacy of such GFs sources, as well to improve the mechanical 
stability of PRP/PL based materials.  
7. Clinical applications of platelet-rich plasma  
The clinical application of PRP has been documented in many fields. In particular, 
recent works described that PRP improves the wound healing process, being able to promote 
tissue regeneration and accelerate bone formation. An example of this, is the work from A. 
Patel et al that showed the positive influence of PRP in the wound healing process in patients 
submitted to cardiac surgery. The use of PRP decreased the incidence of infections derived 
from sternotomy65. Such results suggest that the use of PRP may decrease the incidence and 
costs of sternal wound complications following cardiac surgery.  
In recent years, PRP injections have been used as treatment of musculoskeletal 
conditions like rotator cuff tears66, knee osteoarthritis67, ulnar collateral ligament tears68, 
lateral epicondylitis69, hamstring injuries70 and Achilles tendinopathy71. Total knee 
arthroplasty is a common orthopedic procedure for restoring knee function. M. J. Gardner et 
al studied the efficacy of PRP in pain control and blood loss in this procedure15. They 
concluded that the group who receive PRP treatment required less drugs, achieved higher 
functional range of motion earlier than control group and also had a lower postoperative 
decrease in hemoglobin. Also W. J. Berghoff et al14 showed that PRP, when used in total 
knee arthroplasty, helps in the recovery process. A. K. Mishra et al evaluated the use of PRP 
treatment in patients with chronic tennis elbow72. Results showed that after 24 weeks PRP-
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treated patients had an improvement in their pain scores as also in elbow tenderness. Surgery 
recovery process are difficult and painful, however, such results showed that these can be 
overcome if PRP is used as a treatment.  
A number of studies have focused on how PRP and PL affect osteoblasts, osteoclasts 
and mesenchymal osteoprogenitor stem cells so it can be considered a therapeutic product 
for bone and cartilage repair. N. Labibzadeh et al were pioneers reporting the treating of 
long bone nonunion73. By implanting mesenchymal stromal cells in combination with PL 
into bone injury sites of seven patients, the authors concluded that harvest, isolation and 
implantation of mesenchymal stromal cells combined with PL is safe for treating bone 
nonunion. Despite its use, there has been conflicting evidence about the effectiveness of PRP 
in treating bone and cartilage74,75. More studies are needed to determine the efficacy of using 
PRP to manage musculoskeletal disorders. 
PRP is widely known because of its capacity of improving wound healing process, 
S. Suryanarayan et al carried out a study to evaluate the efficacy of using autologous PRP in 
chronic nonhealing leg ulcers treatment76. Patients with leg ulcers submitted to a treatment 
with PRP showed that not only PRP helps in healing process but also it helps in pain 
reduction. K. Kazakos et al studied the efficacy of a PRP gel in acute limb soft tissue wounds, 
demonstrating that in patients treated with PRP gel healing process was faster77. 
Progressive hemifacial atrophy is a degenerative condition characterized by a slow 
and progressive atrophy of one side of the face. The pathogenesis of the syndrome is not 
clearly understood, however V. Cervelli and P. Gentile78 studied the influence of PRP in this 
pathology. The treatment with PRP mixed with fat tissue favors tissue growth and also 3D 
face reconstruction.  
Most recently, the application of PRP in neuropathies has been studied. Although 
most of the studies are in vitro and in vivo, there are already some clinical trials showing that 
PRP injection could be an improvement on neuropathies recovery79. S. Anjayani et al carried 
out a study on the effectiveness of PRP injections in patients with leprosy peripheral 
neuropathy80. PRP injection was able to stimulate nerve regeneration and also promote pain 
reduction, which means that PRP injections in perineural nerves of leprosy peripheral 
neuropathy patients it’s a good way to improve their recovery. 
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Overall, these results indicated that PRP has a great potential in different clinical 
applications. Nevertheless, more scientific research with well design studies and larger 
samples sized will have to conclude PRP effectiveness before it is more widely covered. 
8. Platelet-rich plasma market assessment 
PRP market was evaluated at US$ 201.2 million in 2016 but it is expected to grow 
in the next years81. Nowadays autologous PRP segment dominates the global PRP market, 
however, it is expected that allogenic PRP segment grows up because of its cost effectiveness 
and safety. PRP application is still dominated by orthopedic segment but its application in 
other areas is emerging very quickly. Clinical areas such as neurology, plastic surgery and 
general surgery may become major users of this therapy. 
Assessing the different types of PRP we can obtain, namely pure PRP, leukocyte-
rich PRP, pure platelet-rich fibrin and leukocyte-rich platelet-rich fibrin, pure PRP is the 
most preferred PRP type, accounting for over 40% share of the overall market. The largest 
market for PRP in 2016 was North America with a share of 43.3% followed by Europe, the 
second largest share of the global PRP market in 2016. The top five players of this market 
are Zimmer Biomet, Stryker Corporation, DePuy Synthes, Harvest Technologies and 
Arthrex, Inc, accounting for more than 70% of the total market share in 2016. Currently, 
most of these key players are domiciled in North America, nevertheless they are focusing on 
expanding and be presence in a larger geographic area, mainly in Asia Pacific which is the 
most lucrative market.  
9. Conclusions and future directions 
The patient's own plasma, PRP and derivatives as therapeutics have found application 
in many fields. An advantage of PRP therapies is the simulation of the physiological repair 
process by releasing autologous GFs. PRP is a promising alternative to animal derived 
supplements based on the efficacy of autologous GFs to accelerate tissue healing, allowing 
a fast recovery after muscles, ligaments, tendon or cartilage lesions. Still, depending on the 
preparation technique, PRP composition may be affected. This means that more research is 
need for the development of standardized protocols. An improved characterization of this 
complex mixture of biomolecules is also imperative and the application of advanced 
proteomic techniques for an effective categorization of the protein and GFs content could be 
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particularly useful on that. PRP is indeed an excellent source of GFs and signaling molecules 
and several works have been reporting on their use in wound healing and tissue regeneration. 
The use of autologous PRP and cells is now an effective alternative in regenerative medicine 
and tissue engineering. In the case of biomaterials based on PRP or combined with PRP and 
its derivatives, they possess attractive bioactivity but weak mechanical properties. New 
strategies to improve the in vitro and in vivo stability of these materials are being explored. 
Finally, from a structural point of view, new strategies will be required to produce PRP-
based devices with improved mechanical properties for load bear applications and with tuned 
degradation rates that could follow the regenerative process.   
 
 
Figure II.4. PRP/PL acquisition process and PRP/PL based biomaterials and clinical applications. 
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1. Platelet lysates 
Platelets are an important source of growth factors (GFs), cytokines and other 
molecules involved in  tissue regeneration1. Platelet-rich plasma (PRP) is obtained from a 
whole blood sample by differential centrifugation and has high platelet concentration, at 
least 1x106 platelets/μL in 5 mL of plasma2,3. Platelet lysates (PL) are obtained from PRP by 
freeze/thaw cycles in order to allow platelet disruption4,5. PRP and PL are both autologous 
sources of GFs and other molecules involved in cell proliferation and differentiation and 
have been used as a possible therapy since 1990s6,7. In this work PL (STEMCELL 
Technologies, Canada) were stored at -20ºC and thawed in a 37ºC water bath with low 
agitation before use. 
2. Chemical modification of platelet lysates 
Since many polymers are not reactive in its native structure, insertion of chemical 
modifications in order to make them responsive to a stimulus like pH changes, light or 
temperature is a widely used procedure for development of new materials8–13.  
Methacrylation of polymeric backbones is one of the possible polymer modifications. 
It can be performed with reagents such as glycidyl methacrylate, methacryloyl chloride or 
methacrylic anhydride (MA). MA, which was used in this work for PL modification, seems 
to provide greater control over the crosslinking density, because methacrylate groups restrict 
the maximum crosslinking density achievable independent of the amount of initiator added 
or experimental conditions like time and temperature8–10,14.  
Methacrylamide and methacrylate groups can be inserted in a protein/peptide chain, 
as figure III.1 shows. The methacryloyl groups added to the polymeric backbone are 
functional groups capable of covalent crosslinking by free radical polymerization in presence 
of a photoinitiator upon ultraviolet (UV) radiation 9,15,16. 
In order to make PL photoresponsive, in this work, a chemical modification using 
MA 94% (Sigma-Aldrich, Germany) was performed. The PL reaction with MA was 
performed at room temperature during 4 hours and with pH maintained between 6-8, in order 
to achieve methacryloyl PL (PLMA). After 4 hours of reaction, the PLMA were purified by 
dialysis with Float-A-Lyzer G2 Dialysis Device 3.5-5 kDa (Spectrum, USA) against 
deionized water during 20-24h to remove the excess of MA. The PLMA solution was filtered 
with a 0.2 µm filter in order to sterilize it, frozen with liquid nitrogen, lyophilized and stored 
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at 4ºC until further use. Two degrees of modification were achieved: low-degree of 
modification (PLMA100) and high-degree of modification (PLMA300). 
 
Figure III.1. Protein/peptide modification with methacrylic anhydride. Methacrylamide and methacrylate 
groups inserted in protein/peptide chain will allow photopolymerization.  
3. PLMA characterization 
3.1. 1H NMR 
NMR analysis were made in order to verify the functionalization of original PL. 
Methacryloyl groups can be detected by 1H NMR spectroscopy since these groups have 
double bound protons and also protons from the methyl group that can be detected. 1H NMR 
analysis of methacrylated polymers prove the methacrylation by the appearance of 
distinctive peaks in the double bond region at δ 5.2 – 5.6 ppm and a peak that corresponds 
to the -CH3 of the methacrylate groups at δ ≈ 2 ppm16. For PL and PLMA characterization 
by 1H NMR, solutions of 10 mg/mL in dimethyl sulfoxide (DMSO) (Fisher Scientific, USA) 
were prepared and analyzed with 18 seconds relaxation delay and 300 scans. The 1H NMR 
spectra were recorded on a Bruker AMX 300 spectrometer at 300.13 MHz. 
3.2. Mass spectrometry 
Mass spectrometry has become a powerful method for protein characterization. 
Protein can be modified in order to module their function and characterization of modified 
proteins can be done by mass spectrometry. This characterization is possible due to the 
increase or decrease of the molecular mass of the affected amino acid residue detected by 
mass spectrometry analysis17. In this work, identification of proteins and modified proteins 
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in PL and PLMA, respectively, was performed on a TripleTOF 6600 mass spectrometer after 
protein digestion with trypsin.  
4. Hydrogel formation 
Photocrosslinking is a simple technique used to fabricate three-dimensional (3D) 
hydrogel networks9 by using a light source and a photoinitiator or crosslinker molecule18,19. 
This technique require light exposure of a solution with crosslinkable components to induce 
covalent crosslinking between neighboring chains18.  For some time now, photosensitive 
biomaterials have been developed providing a platform in which application of light can be 
used to introduce control of crosslink formation12. It is a commonly applied method and until 
now there are no reported adverse effects on cell viability and function10,20. 
Photocrosslinking has some advantages compared to other crosslinking techniques because 
it is cost-effective, rapid, can be carried out under mild conditions and allows fabrication of 
very controlled shape and size hydrogels 9. It also may limit the need for invasive surgical 
procedures because it allows to a trans-tissue in situ polymerization after the material is 
injected or placed in the injury site and irradiated19,21. 
Addition of groups like acrylate moieties to the polymeric backbone can be used to 
provide light polymerization in order to obtain a hydrogel. Therefore, in this work, PLMA 
when in solution and by UV irradiation are able to form hydrogels. Lyophilized PLMA were 
dissolved in a solution of 0.5% (w/v) 2-hydroxy-4’-(2-hydroxyethoxy)-2-
methylpropiophenone (Sigma-Aldrich) in PBS (Sigma-Aldrich) to final concentrations of 
10% or 15% (w/v) PLMA. Hydrogels were prepared by pipetting the polymer solution to 
polydimethylsiloxane (PDMS) (Dow Corning, USA) molds with 3.5mm or 6mm diameter 
followed by UV irradiation (1.54 W/cm2) during 60s. 
5. PLMA hydrogels characterization 
5.1. Mechanical properties 
Mechanical properties of hydrogels play a key role in cell behavior and are important 
characteristics in tissue engineering approaches. The mechanical properties are dependent 
of the used polymer, crosslinking density and swelling22,23. These parameters may be 
adjusted in order to prepare the appropriate hydrogel functions and promotion of new tissue 
formation. Cell adhesion and proliferation processes are heavily influenced by hydrogel 
mechanical properties22. Some changes in hydrogel stiffness may affect oxygen and nutrient 
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permeability, availability of binding sites and water content24. The mechanical behaviour of 
PLMA hydrogels was characterized on the basis of compression tests employing a Universal 
Mechanical Testing Machine Shimadzu MMT-101N (Shimadzu Scientific Instruments, 
Kyoto, Japan) equipped with a load cell of 100N. To this end, both unidirectional and cyclic 
compression assays were performed at room temperature on as-prepared cylindrical 
hydrogels specimens with a diameter of 3.5 mm and height of 2 mm. The nominal stress was 
obtained by dividing the compressive load by the initial (uncompressed) cross-sectional area 
of the specimen. The Young’s modulus was defined as the slope of the linear region of the 
strain/stress curve, corresponding to 0–25% strain. Ultimate stress and ultimate strain values 
were taken as the point where failure of the hydrogel occurred. 
5.2. Scanning electron microscopy 
Scanning electron microscopy (SEM) analysis was performed in order to analyze the 
hydrogels structure. SEM images were also used to study the porosity of the hydrogels by 
measuring the pore size using Image J software. The hydrogels were frozen with liquid 
nitrogen and then lyophilized. Samples were sputter-coated with gold and imaged via SEM 
using Ultra-high Resolution Analytical Scanning Electron Microscope HR-FESEM Hitachi 
SU-70 (Hitachi, Tokyo, Japan). 
5.3. Water content 
Water content is an important property of hydrogels. In this work, hydrogel samples 
of PLMA100 and PLMA300 at 10% and 15% (w/v) were made in triplicate and immersed 
in 5 mL of PBS. Samples were incubated at room temperature during 2 hours. After 2 hours 
the wet weight (ww) was measured and samples were frozen and lyophilized. After 
lyophilization, dry weight (wd) was measured and compared with the initial wet weight. The 
water content was calculated according to following equation: 
Water content (%) =  
ww − wd
ww
× 100 
6. Quantification of proteins and growth factors release 
PRP and PL have high content of GFs3,25,26 and therefore PLMA hydrogels can be a 
source of GFs derived from used PL. For GFs release assays, six samples of each PLMA100 
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at 10% and 15% (w/v) were made. Samples were added to falcons with 5 mL of PBS 
(Thermo Fischer Scientific, USA). The samples were incubated in a bath at 37ºC with 
constant agitation (60 rpm). At each time point, an aliquot of 600 µL was taken from each 
sample and 600 µL of fresh PBS added. Collected samples were stored at -20ºC. Total 
protein quantification was performed with Micro BCA Protein Assay Kit (Thermo Fisher 
Scientific). Quantification of specific proteins and GFs was performed by ELISA assay.  
7. In vitro cell encapsulation 
7.1. Cell culture 
The biological performance of PLMA hydrogels was assessed using L929 Cell Line 
(European Collection of Authenticated Cell Cultures (ECACC)) and human adipose stem 
cells (hASCs) (ATCC).  
L929 cells were cultured in DMEM low glucose, supplemented with sodium 
bicarbonate, 10% FBS and 1% antibiotic/antimycotic. Cells were used between passages 3 
and 25.   
Stem cells are capable of self-renew and differentiation along multiple lineage 
pathways what makes them really interesting for tissue engineering area. hASCs and other 
stem cells are promise as a therapy and treatment of a wide range of medical conditions. 
hASCs can be isolated from adipose tissue, which is an abundant source of hASCs capable 
of differentiate in multiple lineages27. hASCs were cultured in Minimum Essential Alpha 
Medium supplemented with sodium bicarbonate, 10% of FBS and 1% 
antibiotic/antimycotic. hASCs were used until passage 5. Cell suspensions were prepared by 
trypsinization (trypsin/EDTA solution, Sigma-Aldrich). The cells were incorporated into the 
PLMA solutions to a final concentration of 2x106 cells/mL in the case of L929 and 3x106 
cells/mL for hASCs. The hydrogels were prepared as described previously in section 4. 
7.2. Biological evaluation of developed materials 
7.2.1. Cell viability and proliferation 
7.2.1.1. Live/Dead test 
Live/Dead assay was performed in order to assess the L929 and hASCs viability 
inside the hydrogels. This test allows the visualization, simultaneously, of the live and dead 
cells by fluorescence microscopy. Acetomethoxy derivative of calcein (Calcein AM) is non-
fluorescent dye that easily permeates live cells where it is converted in calcein (green 
fluorescent die). Propidium iodide (PI) permeates damaged cells and binds to the nucleic 
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acids, staining them in red. At pre-determined time points, hydrogels were incubated in a 
solution of 2μL of Calcein AM 4mM solution in DMSO (Life Technologies, Thermo Fisher 
Scientific, USA) and 1μL of PI (Thermo Fisher Scientific, USA) in 1000μL of PBS at 37ºC 
during 30 minutes. After washing with PBS, hydrogels were examined using a fluorescence 
microscope (Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss, Germany).  
7.2.1.2. Cell metabolic activity quantification 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, USA) was 
performed to evaluate cell viability inside the hydrogels. A solution of 1:10 MTS 
reagent:PBS was made and after wash hydrogels with PBS they were incubated with MTS 
solution overnight at 37ºC. The quantification was achieved by measuring absorbance at 
490nm. Triplicates were made for each sample and per culturing time. 
7.2.1.3. Cell proliferation by DNA quantification 
DNA quantification to evaluate cell proliferation was performed using a Quant-iT 
PicoGreen dsDNA kit (Invitrogen, Thermo Fisher Scientific, USA). While bounded to 
dsDNA, PicoGreen dye is excited by UV light allowing the measurement of the produced 
fluorescence. Briefly, at pre-determined time-points hydrogels were washed with PBS, 
incubated in sterile deionized water and frozen at -80ºC. In order to induce disruption of the 
cells inside the hydrogel, the samples were thawed at 37ºC and placed in an ultrasounds bath 
during approximately 30 minutes. Standards were prepared with concentrations ranging 
between 0 and 2 ug/mL. The plate was incubated for 10 min in the dark and fluorescence 
was measured using an excitation wavelength of 480 nm and an emission wavelength of 528 
nm. Triplicates were made for each sample and per culturing time. 
7.2.2. Cell morphology 
7.2.2.1. Immunostaining 
A DAPI/Phalloidin staining was made in order to access cell morphology in 
hydrogels. At pre-determined time-points hydrogels were washed with PBS and fixed with 
a 4% formaldehyde (Sigma-Aldrich) solution during at least 2 hours. For DAPI/Phalloidin 
staining, a phalloidin solution (Flash Phalloidin™ Red 594, 300U, Biolegend, USA) was 
diluted 1:40 PBS and hydrogels were incubated at room temperature in phalloidin solution 
during 45 min. After PBS washes, a DAPI (DAPI (4',6-diamidino-2-phenylindole, 
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dihydrochloride), Thermo Fisher Scientific) solution was diluted in 1:1000 PBS and 
hydrogels were incubated during 5 minutes with this solution also at room temperature. 
DAPI binds to DNA staining in blue the nucleus and phalloidin binds to the cytoskeleton 
filaments showing them in red at fluorescence microscope. After washes with PBS, 
hydrogels were examined using a fluorescence microscope (Fluorescence Microscope Zeiss, 
Axio Imager 2, Zeiss, Germany). 
7.3. Fabrication of PLMA microstructures 
Lyophilized PLMA were dissolved in 0.5% (w/v) 2-hydroxy-4’-(2-hydroxyethoxy)-
2-methylpropiophenone (Sigma-Aldrich) in PBS (Sigma-Aldrich) to a final concentration of 
10% (w/v). L929 cells were incorporated into the PLMA solution to a final density of 2x106 
cells/mL. 50µL of this solution were poured onto a glass coverslip. Then, PDMS mold was 
brought into contact with the solution and pressed. The mold was exposed to UV irradiation 
(1.54 kW/cm2) during 60s. Finally the PDMS mold was removed from the glass and the 
hydrogels were cultured during 7 days. A DAPI/Phalloidin staining was performed as 
described in 7.2.2.1 at 7 days of incubation and PLMA hydrogels were visualized using a 
fluorescence microscope (Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss). 
8. Statistical analysis 
All data were subjected to statistical analysis and were reported as a mean ± standard 
deviation. Statistical differences between the analyzed groups were determine by unpaired t 
test. 
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Figure III.2. Abstract scheme of the methods used in this work. 
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Abstract 
 Regenerative medicine and tissue engineering (TE) aim the development of new 
tissue therapies capable of restore and maintain tissue function. Platelet-rich plasma (PRP) 
and human platelet lysates (PL) are attractive autologous sources of growth factors (GFs) 
and other molecules involved in the tissue regeneration process. PRP and PL have been 
mainly explored as a promising non-xenogenic serum supplement designed for the 
expansion of human cells that replaces fetal bovine serum. Recently, PRP/PL based scaffolds 
have been investigated as cell culture platforms for TE applications. Despite all the 
promising results, in most cases this type of materials have poor mechanical properties and 
also poor stability in vitro.  In an attempt to overcome such limitations, we developed and 
characterize PL based hydrogels with tunable mechanical properties. PL were modified by 
addition of methacryloyl groups that by exposure to ultraviolet (UV) irradiation were 
capable of forming hydrogels. Our results showed that the achieved materials own increased 
mechanical properties that can be easily adjustable by changing methacryloyl PL (PLMA) 
concentration or PLMA modification degree. Additionally, PLMA hydrogels enabled 
sustained release of VEGF and fibrinogen for up to 250 hours and were resistant to protease 
degradation. Human derived stem cells and murine fibroblasts were successfully 
encapsulated in the hydrogels, exhibiting high cell viability, adhesion and proliferation. 
These results support the use of a PLMA hydrogel as a scaffold for stem cell culture and 
GFs release. We hypothesize that PLMA hydrogels may be an alternative to the gold 
standards for three-dimensional (3D) cell culture, namely Matrigel and collagen. The 
material here developed could have an autologous origin, being adequate to produce 
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customized robust matrices to be used as general platform for 3D cell culture with no risk of 
cross reactivity, immune reaction or disease transmission. 
Introduction 
Tissue engineering (TE) encompasses biological science and engineering in order to 
develop biological substitutes that can restore and maintain normal tissue function1,2. 
Although human body has the capacity to remodel and regenerate small defects, severe 
injuries or large defects are harder or even impossible to heal on its own3. Currently, 
therapies based on organ and tissue transplantation are widely used, however the lack of 
donors and also the severe immune complications are limitation of this strategy. So TE may 
be the answer to bypass these obstacles1,4. 
Hydrogels are soft three-dimensional (3D) insoluble hydrophilic network systems 
with high water content, that allow for an easy transport of oxygen, nutrients and cell 
metabolites. Due to its similarities with extracellular matrix (ECM) both structural and 
compositional level, hydrogels have received particular attention. Among other applications, 
hydrogels have been used as a platform for cell culture since they may promote cellular 
proliferation and survival5–8.  
Platelet-rich plasma (PRP), obtained from whole blood by a differential 
centrifugation process, is an autologous source of growth factors (GFs), cytokines and other 
protein9–11. Human platelet lysates (PL) are derivatives obtained from PRP by freeze/thaw 
cycles12,13. Previous works have reported the potential of PRP based materials for cell 
culture14,15. Moreover, PRP and PL have been used as an autologous material containing 
bioactive molecules, locally enhancing wound healing16–19, bone growth and cartilage 
repair20–23 and tissue sealing24. PRP and PL hydrogels have also been explored as 3D cell 
culture platforms and for tissue regeneration purposes. The major disadvantages of these 
hydrogels are their poor mechanical and poor stability in vivo and cell culture conditions 
which hinders its application. The main goal in this study was the development of hydrogels 
made of PL with increased mechanical properties and improved stability. Here we proposed 
the modification of PL by chemical conjugation with a photoresponsive group in order to 
achieve PL-based photopolymerizable materials with controlled mechanical properties. 
Such PL derived materials should provide a functional support for cell growth and interact 
with cells to control their function, guiding the process of tissue morphogenesis. Matrigel or 
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collagen matrices have shown to drive cellular self-organization and complex 
morphogenetic processes to result in sophisticated platforms for cell culture25. However, TE 
strategies using this type of materials goes against current animal-free approaches for cell 
culture. As an alternative to animal-based gels, synthetic polymer-based gels have also been 
developed to recreate native cell microenvironments26. Despite the design flexibility for 
specific applications, such synthetic systems are typically expensive and their synthesis can 
be time consuming, requiring often multiple steps. In the current era, striving toward 
personalized medicine and targeted therapy, creating the most appropriate material that 
closely mimics the in vivo microenvironment is one of the most important topics to address. 
Compared with using hydrogels, this method is advantageous in creating bioactive hydrogels 
without complicated synthesis for bioconjugation and no risk of cross reactivity, immune 
reaction or disease transmission. 
We hypothesized that such blood-delivered hydrogels that could have an autologous 
origin, could be adequate to produce customized robust matrices rich in bioactive factor, 
adequate to be used as general platform for 3D cell cultures and in TE strategies. 
Materials and methods 
1. Synthesis of methacryloyl platelet lysates  
Methacryloyl PL (PLMA) were synthesized by reaction with methacrylic anhydride 
94% (MA) (Sigma-Aldrich, Germany). PL (STEMCELL Technologies, Canada) were 
thawed at 37ºC, to 10ml of this solution, either 100 or 300μL of MA was added, in order to 
synthesize PLMA100 (low-degree of modification) or PLMA300 (high-degree of 
modification), respectively. The reaction was performed under constant stirring during 4 
hours at room temperature. pH was controlled and maintained between 6-8 by addition of 
5M sodium hydroxide (NaOH) (AkzoNobel, USA) solution. During the first hour of reaction  
pH was constantly adjusted and then re-adjusted every 15 minutes. After 4 hours of reaction, 
the PLMA were purified by dialysis with Float-A-Lyzer G2 Dialysis Device 3.5-5 kDa 
(Spectrum, USA) against deionized water during 20-24h to remove the excess of MA. The 
PLMA solution was filtered with a 0.2 µm filter in order to sterilize it, frozen with liquid 
nitrogen, lyophilized and stored at 4ºC until further use. 
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2. PLMA characterization 
2.1. 1H NMR 
NMR analysis were made in order to verify the functionalization of original PL. 
Solutions of 10 mg/mL of original PL and of each PLMA modification degree in dimethyl 
sulfoxide (DMSO) (Fisher Scientific, USA) were prepared and analyzed by 1H NMR with 
18 seconds relaxation delay and 300 scans. The 1H NMR spectra were recorded on a Bruker 
AMX 300 spectrometer at 300.13 MHz. 
2.2. Mass spectrometry 
Mass spectrometric identification of proteins and modified proteins in PL and 
PLMA, respectively, was performed on a TripleTOF 6600 mass spectrometer after protein 
digestion with trypsin.  
3. Hydrogel formation 
Lyophilized PLMA were dissolved in a solution of 0.5% (w/v) 2-hydroxy-4’-(2-
hydroxyethoxy)-2-methylpropiophenone (Sigma-Aldrich) in PBS (Sigma-Aldrich) to final 
concentrations of 10% or 15% (w/v) PLMA. Hydrogels were made by pipetting the polymer 
solution to polydimethylsiloxane (PDMS) (Dow Corning, USA) molds with 3.5mm or 6mm 
diameter followed by ultraviolet (UV) irradiation (1.54 W/cm2) during 60s. 
4. PLMA hydrogels characterization 
4.1. Mechanical properties 
The mechanical behavior of PLMA hydrogels was characterized on the basis of 
compression tests employing a Universal Mechanical Testing Machine Shimadzu MMT-
101N (Shimadzu Scientific Instruments, Kyoto, Japan) equipped with a load cell of 100N. 
To this end, both unidirectional and cyclic compression assays were performed at room 
temperature on as-prepared cylindrical hydrogels specimens with a diameter of 3.5 mm and 
height of 2 mm. The nominal stress was obtained by dividing the compressive load by the 
initial (uncompressed) cross-sectional area of the specimen. The Young’s modulus was 
defined as the slope of the linear region of the strain/stress curve, corresponding to 0–25% 
strain. Ultimate stress and ultimate strain values were taken as the point where failure of the 
hydrogel occurred. 
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4.2. Scanning electron microscopy 
The hydrogels were frozen with liquid nitrogen and then lyophilized. Samples were 
sputter-coated with gold and imaged via SEM using Ultra-high Resolution Analytical 
Scanning Electron Microscope HR-FESEM Hitachi SU-70 (Hitachi, Tokyo, Japan). SEM 
images were analyzed by Image J software for pore size measurement.  
4.3. Water content 
Hydrogel samples of PLMA100 and PLMA300 at 10% and 15% (w/v) were made in 
triplicate and immersed in 5 mL of PBS. Samples were incubated at room temperature during 
2 hours. After 2 hours the wet weight (ww) was measured and samples were frozen and 
lyophilized. After lyophilization, dry weight (wd) was measured and compared with the 
initial wet weight. The water content was calculated according to following equation: 
Water content (%) =  
ww − wd
ww
× 100 
5. Quantification of protein and growth factors release 
For the release assays, six samples of each PLMA100 at 10% and 15% (w/v) were 
made. Samples were added to falcons with 5 mL of PBS (Thermo Fischer Scientific, USA). 
The samples were incubated in a bath at 37ºC with constant agitation (60 rpm). At each time 
point, an aliquot of 600 µL was taken from each sample and 600 µL of fresh PBS added. 
Collected samples were stored at -20ºC. Total protein quantification was performed with 
Micro BCA Protein Assay Kit (Thermo Fisher Scientific). Quantification of specific proteins 
and GFs was performed by ELISA assay.  
6. In vitro cell culture 
6.1. Cell culture and encapsulation 
The biological performance of PLMA hydrogels was assessed using the L929 Cell 
Line (European Collection of Authenticated Cell Cultures (ECACC)) and hASCs (ATCC). 
L929 cells were cultured in Dulbecco's Modified Eagle's Medium low glucose, 
supplemented with sodium bicarbonate, 10% FBS and 1% antibiotic/antimycotic. Cells were 
used between passages 3 and 25.  hASCs were cultured in Minimum Essential Alpha 
Medium supplemented with sodium bicarbonate, 10% of FBS and 1% 
antibiotic/antimycotic. hASCs were used until passage 5. Cell suspensions were prepared by 
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trypsinization (trypsin/EDTA solution, Sigma-Aldrich). The cells were incorporated into the 
PLMA solutions to a final concentration of 2x106 cells/mL in the case of L929 and 3x106 
cells/mL for hASCs. The hydrogels were prepared as described previously in section 3. 
6.2. Live/Dead assay 
 At pre-determined time points, hydrogels were incubated in a solution of 2μL of 
Calcein AM 4mM solution in DMSO (Life Technologies, Thermo Fisher Scientific, USA) 
and 1μL of Propidium iodide (PI) (Thermo Fisher Scientific, USA) in 1000μL of PBS at 
37ºC during 30 minutes. After washing with PBS, hydrogels were examined using a 
fluorescence microscope (Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss, Germany).  
6.3. Cell metabolic activity quantification 
 CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, USA) was 
used. After each time point, hydrogels were washed with PBS and incubated in a solution of 
MTS reagent diluted 10x in PBS. Samples were then incubated overnight at 37ºC, protected 
from light. The quantification was achieved by measuring absorbance at 490nm. Triplicates 
were made for each sample and per culturing time. 
6.4. Cell proliferation by DNA quantification 
DNA quantification was performed using a Quant-iT PicoGreen dsDNA kit 
(Invitrogen, Thermo Fisher Scientific, USA). Briefly, at pre-determined time-points 
hydrogels were washed with PBS, incubated in sterile deionized water and frozen at -80ºC. 
In order to induce disruption of the cells inside the hydrogel, the samples were thawed at 
37ºC and placed in an ultrasounds bath during approximately 30 minutes. Standards were 
prepared with concentrations ranging between 0 and 2 ug/mL. The plate was incubated for 
10 min in the dark and fluorescence was measured using an excitation wavelength of 480 
nm and an emission wavelength of 528 nm. Triplicates were made for each sample and per 
culturing time. 
6.5. Cell morphology analysis 
A DAPI/Phalloidin staining was made in order to access cell morphology in 
hydrogels. At pre-determined time-points hydrogels were washed with PBS and fixed with 
a 4% formaldehyde (Sigma-Aldrich) solution during at least 2 hours. For DAPI/Phalloidin 
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staining, a phalloidin solution (Flash Phalloidin™ Red 594, 300U, Biolegend, USA) was 
diluted 1:40 PBS and hydrogels were incubated at room temperature in phalloidin solution 
during 45 min. After PBS washes, a DAPI (DAPI (4',6-diamidino-2-phenylindole, 
dihydrochloride), Thermo Fisher Scientific) solution was diluted in 1:1000 PBS and 
hydrogels were incubated during 5 minutes with this solution also at room temperature. After 
washing with PBS, hydrogels were examined using a fluorescence microscope 
(Fluorescence Microscope Zeiss, Axio Imager 2, Zeiss, Germany). 
6.6. Fabrication of PLMA microstructures 
Lyophilized PLMA were dissolved in 0.5% (w/v) (w/v) 2-hydroxy-4’-(2-
hydroxyethoxy)-2-methylpropiophenone (Sigma-Aldrich) in PBS (Sigma-Aldrich) to a final 
concentration of 10% (w/v). L929 cells were incorporated into the PLMA solution to a final 
concentration of 2x106 cells/mL. 50µL of this solution were poured onto a glass coverslip. 
Then, PDMS mold was brought into contact with the solution and pressed. The mold was 
exposed to UV irradiation (1.54 kW/cm2) during 60s. Finally the PDMS mold was removed 
from the glass and the hydrogels were cultured during 7 days. A DAPI/Phalloidin staining 
was performed as described in 7.2.2.1 at 7 days of incubation and PLMA hydrogels were 
visualized using a fluorescence microscope (Fluorescence Microscope Zeiss, Axio Imager 
2, Zeiss). 
7. Statistical analysis 
All data were subjected to statistical analysis and were reported as a mean ± standard 
deviation. Statistical differences between the analyzed groups were determine by unpaired t 
test. 
 
Results and discussion 
1. Synthesis and PLMA characterization 
Human platelets are an autologous source of multiple proteins, GFs and cytokines 
that can be extracted by platelet lysis27. In this study, PL based hydrogels with tunable 
physical properties that can be used for cell encapsulation or as substrates for two-
dimensional (2D) cell culture were synthesized for the first time.  PLMA were synthesized 
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by reaction of PL with MA. Based on previously published works on the modification of 
gelatin and tropoelastin with methacrylate groups, we developed a protocol for the synthesis 
of PL proteins modified with methacrylate groups8,28–32. Different functional groups in the 
proteins present in PL are sensitive to chemical modifications as depicted in figure IV.1A.  
 
Figure IV.1. A) Methacrylate and methacrylamide groups by reaction of a protein/peptide with methacrylic 
anhydride. B) 1H NMR spectra for PL, PLMA100 and PLMA300 with distinctive peaks characteristics of 
methacrylate groups: double bound methacrylate (1) and -CH3 of methacrylate group (2). 
In particular, the reactive functional groups are located on the side groups of amino 
acid residues, including hydroxyl groups, amino groups, and carboxylic acid substitutes. 
Different degrees of methacrylation could be obtained by varying the molar ratio of MA to 
PLs concentration. In this work two degrees of modification were achieved: PLMA100 and 
PLMA300.  The degree of conversion with MA groups (i.e. degree of methacrylation) in 
biopolymers has conventionally been determined using 1H NMR spectroscopy. Since PL is 
a mixture of proteins and GFs with complex compositions, it might not be feasible to detect 
and differentiate the resonance peaks from methacrylamide and methacrylate groups from 
1H NMR spectra. Nevertheless, 1H NMR analysis to PLMA confirmed the methacrylation 
of PL by the appearance of distinctive peaks in the double bond region (δ 5.2 – 5.6 ppm) 
(figure IV.1B) and a sharp peak that corresponds to the -CH3 of the methacrylate groups (δ 
≈ 2 ppm) (figure IV.1B) on the modified PL spectra.  
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PL and PLMA samples were digested with trypsin in order to obtain small peptides. 
After protein digestion, mass spectrometry analysis was performed. Results show that human 
serum albumin is the most abundant protein in the PL mixture. Platelets, contain more than 
1100 different proteins, with numerous post-translational modifications, resulting in over 
1500 protein-based bioactive factors. Table IV.1. summarizes the main components found 
in the PL starting samples and MA modified samples. Results demonstrated that the main 
components of PL did not significantly change upon conjugation of protein PL with 
methacrylate groups. 
 PL PLMA100 PLMA300 
1 Serum albumin Serum albumin Serum albumin 
2 Apolipoprotein B-100 Serotransferrin Complement C3 
3 Complement C3 Complement C3 Serotransferrin 
4 Alpha-2-macroglobulin Alpha-2-macroglobulin Alpha-2-macroglobulin 
5 Serotransferrin Keratin, type II cytoskeletal 1 Apolipoprotein B-100 
6 Complement C4-B Apolipoprotein B-100 Keratin, type II cytoskeletal 1 
7 Keratin, type I cytoskeletal 10 Keratin, type I cytoskeletal 9 Alpha-1-antitrypsin 
8 Immunoglobulin gamma-1 heavy chain Apolipoprotein A-I Keratin, type I cytoskeletal 10 
9 Keratin, type II cytoskeletal 1 Keratin, type I cytoskeletal 10 Haptoglobin 
10 Apolipoprotein A-I Haptoglobin Apolipoprotein A-I 
11 Alpha-1-antitrypsin Immunoglobulin gamma-1 heavy chain Complement C4-B 
12 Haptoglobin Alpha-1-antitrypsin 
Immunoglobulin gamma-1 heavy 
chain 
13 
Keratin, type II cytoskeletal 2 
epidermal 
Keratin, type II cytoskeletal 2 epidermal 
Keratin, type II cytoskeletal 2 
epidermal 
14 Ceruloplasmin Immunoglobulin heavy constant mu Ceruloplasmin 
15 Keratin, type I cytoskeletal 9 Immunoglobulin heavy constant alpha 1 Keratin, type I cytoskeletal 9 
16 Apolipoprotein A-IV Ceruloplasmin Immunoglobulin heavy constant um 
17 Hemopexin Hemopexin Hemopexin 
18 Immunoglobulin mu heavy chain 
Inter-alpha-trypsin inhibitor heavy chain 
H4 
Alpha-1B-glycoprotein 
19 Complement factor B Keratin, type II cytoskeletal 5 
Immunoglobulin heavy constant 
alpha 1 
20 Complement factor H Antithrombin-III 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
21 
Immunoglobulin heavy constant alpha 
1 
Keratin, type I cytoskeletal 14 Actin, cytoplasmic 2 
22 Vitamin D-binding protein Alpha-1B-glycoprotein Immunoglobulin kappa light chain 
23 Complement C5 Actin, cytoplasmic 2 Transthyretin 
24 Actin, cytoplasmic 2 Immunoglobulin kappa light chain Apolipoprotein A-IV 
25 Alpha-1B-glycoprotein 
Immunoglobulin heavy constant gamma 
2 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
26 Fibrinogen gamma chain Complement factor B Antithrombin-III 
27 Fibrinogen alpha chain Alpha-1-acid glycoprotein 1 Vitamin D-binding protein 
28 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
Vitronectin Alpha-1-antichymotrypsin 
29 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
Inter-alpha-trypsin inhibitor heavy chain 
H1 
Complement factor B 
30 Immunoglobulin kappa light chain Kininogen-1 Plasma protease C1 inhibitor 
31 Alpha-1-antichymotrypsin Fibrinogen gamma chain Apolipoprotein E 
32 Antithrombin-III Alpha-1-antichymotrypsin 
Immunoglobulin heavy constant 
gamma 2 
33 Prothrombin Complement C4-B Vitronectin 
34 Apolipoprotein E Apolipoprotein A-IV Fibrinogen gamma chain 
35 Fibrinogen beta chain Angiotensinogen Angiotensinogen 
Table IV.1.  Protein content for PL, PLMA100 and PLMA300. 
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The degree of modification was also evaluated using mass spectrometry. As it was 
expected, mass spectrometry results for PLMA100 reveals less modified peptides with 
methacryloyl groups than in PLMA300 (Table IV.2)  and most of these modification sites 
occur in serum albumin peptides (supporting information). Modification occurs in different 
residues but mainly in lysine (K) and glutamine (Q) residues, as also other researchers 
reported for gelatin and tropoelastin modification with this type of chemical conjugation31.  
Sample Total peptide sequences Modified peptide sequences Degree of modification 
PLMA100 2410 346 14% 
PLMA300 3391 846 25% 
 
Table IV.2. Mass spectrometry results for total number of identified peptides and also the number of modified 
peptides founded. 
 
2. Hydrogel formation  
Hydrogels were formed by photopolymerization upon exposure of a PLMA solution 
to UV irradiation. PLMA are water soluble and its low viscosity allow the preparation of 
PLMA solutions up to 15% (w/v). This characteristic is especially important in injectable 
hydrogels as this way its application is easier and use minimally invasive procedures. 
Another important characteristic of these hydrogels is the fact that the crosslinking occurs 
only in 60s UV exposure at quite low intensity, 1.54 W/cm2. Figure IV.2 shows PLMA 
hydrogels obtained for each modification degree at 10% and 15% (w/v).  
 
Figure IV.2. Crosslinked PLMA hydrogels formed from PLMA100 and PLMA300 at 10% and 15% (w/v). 
 
3. PLMA hydrogels characterization  
3.1. Mechanical tests 
PL based gels formed upon activation of PL concentrates with calcium and thrombin 
have been used as materials for cell culture. Nevertheless, these hydrogels typically present 
poor mechanical properties and are difficult to handle. Moreover, they tend to degrade fast 
in vivo, unless some antifibrinolytic agent is used in order to slow down the degradation 
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process33,34. On the other side, material such as Matrigel and collagen, widely used as cell 
culture have issues with handling. To overcome these limitations, the hydrogels here 
proposed may be easily tuned to present enhanced stability and mechanical properties. We 
tested PLMA hydrogels mechanical properties and how they change by varying PLMA 
modification degree and concentration. Hydrogels were formed by addition of a 
photoinitiator to the PLMA solution followed by photopolymerization with UV irradiation. 
Mechanical assays were performed in hydrogels made from PLMA100 and PLMA300, 
prepared upon UV irradiation (1.54 W/cm2) during 60s. For both PLMA degrees of 
modification is possible to obtain robust hydrogels at 10% and 15% (w/v). Figure IV.3A 
shows the results obtained for compressive stress-strain of PLMA hydrogels.  
 
Figure IV.3. A) Representative compressive stress-strain curves for PLMA100 and PLMA300 hydrogels at 
10% and 15% (w/v). B) Young's modulus (1), ultimate strain (2) and ultimate stress (3) obtained for PLMA100 
and PLMA300 at 10% and 15% (w/v). Statistical analysis through unpaired t test showed significant 
differences (*p < 0.05) between the analyzed groups.  
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The data shown in figure IV.3B-1 shows that Young’s modulus increases with the 
increase in the PLMA concentration. Likewise, an increase in the degree of modification of 
PL, corresponds to an increase in stiffness for the same concentration of polymer. As it can 
be seen, for PLMA100 Young’s modulus at 10% and 15% (w/v) is lower when compared 
with the same concentrations of PLMA300 hydrogels. Figure IV.3B-2 shows the ultimate 
strain for PLMA hydrogels and the influence of polymer concentration and degree of 
modification on these values. The ultimate strain is higher in PLMA 15% (w/v) and also 
higher in PLMA100 modification compared with PLMA300. PLMA300 have less resistance 
to fracture compared to PLMA100 modification hydrogels. This may be due to the higher 
degree of methacrylation, which increases the crosslinking density of hydrogels and also its 
stiffness. Figure IV.3B-3 shows the ultimate stress for each concentration of two different 
modification degrees. An increase in the ultimate stress from the 10% (w/v) to 15% (w/v) 
hydrogels is evident. It is important to point out that PLMA hydrogels are formed rapidly 
within 30 - 60 seconds upon UV irradiation, which is shorter than the typical time (~ 20min 
- 1h) required to crosslink PRP-based gels. 
 Evaluate mechanical properties of hydrogels is an important step in their 
characterization. The mechanical properties play a key role in the stability of the hydrogel 
in culture and in cellular mechanotransduction, this way affecting cellular spreading, 
migration and also differentiation. Provide the ideal features to support cell adhesion and 
proliferation are important characteristics of 3D cell culture platforms35–37. The PLMA 
hydrogels have unique structural properties that allow them to behave as a viscoelastic solid 
with improved mechanical properties compared to PRP based gels so far reported.  
Mechanical properties of PLMA hydrogels may be tuned in the range of 0.5 – 10 
kPa. Therefore, PLMA hydrogels may be used to mimic some native tissues stiffness: brain 
tissue (elasticity 0.1-1 kPa)36,38–40 and striated muscle (elasticity 8-17 kPa)38.  
3.2. Physical properties of PLMA hydrogels 
Hydrogels porosity influences nutrient flux throughout the matrix and is related with 
hydrogel swelling and mechanical properties35. Small molecular porosity is correlated with 
lower swelling ratio and higher modulus35,41,42. Molecular porosity and mechanical 
properties of hydrogels are important characteristics that have to be taken into account due 
to its influence in cell behavior. Penetration of cells into hydrogels, as well as migration, 
proliferation and exchange of oxygen, nutrients and waste materials are process influenced 
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by the hydrogel stiffness43. In order to explore PLMA hydrogels microstructure, SEM 
analysis of dried PLMA gels were performed. PLMA hydrogels have a porous network 
influenced by PLMA concentration as showed in figure IV.4. For lower (10% w/v) PLMA 
concentration, hydrogels have larger porous than in higher (15% w/v) PLMA concentrations. 
Also methacryloyl modification degree influence these porous network, as it can be seen in 
figure IV.4, PLMA300 hydrogels show a decrease in pore size, especially for PLMA300 
15% (w/v).  
 
Figure IV.4. A) Representative cross-section SEM images of PLMA100 and PLMA300 hydrogels at 10% and 
15% (w/v). B) Pore size values obtained for PLMA100 and PLMA300 at 10% and 15% (w/v) hydrogels. C) 
Water content for PLMA100 and PLMA300 hydrogels at 10% and 15% (w/v). Statistical analysis through 
unpaired t test showed significant differences (*p < 0.05) between the analyzed groups. 
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Molecular porosity of PLMA hydrogels is not very different of other protein based 
hydrogels like gelatin methacryloyl43 and it can be tuned by changing some hydrogel 
fabrication parameters, which does not occur for other hydrogels like tropoelastin 
methacrylate based hydrogels32 where pore size is not very different for each low 
modification degree concentration.  
The water content of PLMA hydrogels was also evaluated. Results shown that this 
parameter is not significantly different between all the studied conditions. In general, PLMA 
hydrogels have 90% of water content (Figure IV.4C). 
4. In vitro cell culture studies 
L929 mouse fibroblasts were used in a first screening of the biological performance 
of the PLMA hydrogels. Cells encapsulated in PLMA100 hydrogels at 10% (w/v) were 
cultured during 7 days and at determined time points, namely 1, 3 and 7 days, analysis to 
cell morphology, viability and proliferation were performed. Figure IV.5 shows that cells 
are well distributed within the hydrogel, exhibiting high viability at 1 day and also after 7 
days. DAPI/Phalloidin staining was also performed at days 3 and 7 in order to see cell 
morphology inside the PLMA hydrogels (figure IV.5). The L929 cells adhered, spread and 
proliferated within the PLMA hydrogel. 
 In a second approach, hASCs were used in order to test the potential of PLMA 
hydrogels to support the culture of human derived stem cells. In a first approach, hydrogels 
made of PLMA100 at 10% (w/v) were used for hASCs encapsulation likewise for L929 
culture. However, the results revealed that these hydrogels were not capable to promote 
hASCs adhesion and proliferation.  Based on literature reports that suggest stiffer hydrogels 
for increased hASCs adhesion and proliferation44,45, PLMA100 hydrogels at a 15% (w/v) 
concentration were tested. Live/Dead assay reveal that PLMA hydrogels greatly support cell 
viability up to 7 days in culture (figure IV.5A). Cell morphology was assessed by 
DAPI/Phalloidin staining at 3 and 7 days of culture (Figure IV.5B and 5C). After 3 days in 
culture, cells readily elongated in PLMA hydrogels, after 7 days in culture cells are perfectly 
elongated and migrated, forming interconnected networks with neighboring cells. 
Photopolymerizable hydrogels permit to fix the shape of the solution precursor using 
light. In order to fabricate microstructures of PLMA hydrogels, L929 cells were 
encapsulated in a PLMA100 10% (w/v) hydrogel (figure IV.5D).  Obtained microstructures 
have approximately 800µm and L929 cell are able to proliferate inside these microgels. 
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These results support the idea that PLMA hydrogels can be used as individual 
microstructures for biological tests or as hybrid units that can be then assembled into bigger 
structures.  
 
Figure IV.5. Representative fluorescence images for: A) L929 and hASCs live/dead at 1 and 7 days of culture. 
B and C) L929 and hASCs DAPI/Phalloidin staining at 3 and 7 days of cell culture. (D) DAPI/Phalloidin 
staining for PLMA microstructures of encapsulated L929 at 7 days of culture. 
 
Cell viability and cell proliferation assays were performed by MTS test and DNA 
quantification, respectively (Figure IV.6). L929 as well as hASCs are able to proliferate 
inside PLMA hydrogels as it can be seen by the increasing in DNA quantity and also by the 
results achieved for viability tests. These results are in agreement with previously described 
results for live/dead assay and DAPI/Phalloidin staining, which demonstrated cell spreading 
and proliferation within PLMA hydrogels. 
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Figure IV.6. DNA (A) and MTS (B) results for L929 and hASCs at 1 day, 3 and 7 days of cell culture. 
Statistical analysis through unpaired t test showed significant differences (*p < 0.05) between the analyzed 
groups. 
 
The obtained results showed that PLMA hydrogels can be used as a platform for cell 
culture. Cells maintain their viability for at least 7 days and are able to proliferate inside the 
hydrogels. However, depending on cell type, a specific stiffness of PLMA hydrogels is 
required. hASCs adhesion was poor on PLMA100 10% (w/v) hydrogels and increased with 
an increase of PLMA to 15%, that is associated with increased stiffness. The stiffness of the 
hydrogel is important in cell adhesion and proliferation process and has to be tuned in order 
to obtain the expected results38,44,46,47.  Both cell types readily bound to, proliferated, 
elongated and migrated when encapsulated on PLMA hydrogels. The relatively soft nature 
of PLMA gel likely contributes to the favorable cell invasion and migration. Such results are 
quite promising, thus far, most of the hydrogels used in cell encapsulation require often 
conjugation with specific bioactive molecules34,42,48,49. This may be time consuming and 
costly. The intrinsic ability of PLMA hydrogels to support cell culture is comparable to that 
of Matrigel or collagen. Matrigel or collagen matrices have shown to drive cellular self-
organization and complex morphogenetic processes to result in sophisticated in vitro disease 
models26,50. As an alternative to animal-based gels, synthetic polymer-based gels have also 
been developed to recreate native cell microenvironments. However, they are typically 
expensive and their synthesis can be time consuming, requiring often multiple steps. In 
addition, nowadays there is an effort to switch to animal-free models. We further envisage 
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that PLMA hydrogels may be an alternative to these animal derived materials for 3D cell 
culture.   
5. Protein released from PLMA hydrogels 
PLMA hydrogels here described are a pool of proteins, GFs and other molecules that 
are essential for cell growth and proliferation. We predicted that a fraction of this complex 
mixture of proteins will be loosely bounded to the hydrogel after the photocrosslinking step. 
For this reason, protein and GFs release assays were performed in order to know the profile 
release from PLMA hydrogels. Figure IV.7A shows the total protein release profile from the 
gels used for in vitro cell encapsulation assays, PLMA100 at 10% and 15% (w/v). Protein 
release profile of PLMA hydrogels shows an overall sustained release. In the first 24 hours 
of the assay, protein release is quite fast but between 24 hours and approximately 240 hours 
protein release is well controlled. Using autologous source of GFs instead of using 
recombinant GFs, which are very expensive and have a short half-life, has been proposed51–
53. PLMA hydrogels are a pool of these GFs and they can be potentially used as a platform 
for the release of autologous GFs and bioactive proteins involved in cell recruitment, growth 
and proliferation processes. The vascular endothelial growth factor (VEGF) has the potential 
to promote differentiation of common stem cells to angiogenic cells and has been long 
recognized as an important and necessary step during tissue repair. On the other hand, 
fibrinogen has been recognized as a main component in PRP and is a key element in the 
previous reported PRP based gels. Thus, ELISA assay was performed to investigate the 
release profile of both VEGF and fibrinogen from the PLMA hydrogels. As well as in total 
quantification, the release of fibrinogen and VEGF occurs in a sustained manner as figure 
IV.7B shows.  
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Figure IV.7. Total protein release quantification (A) and ELISA quantification of fibrinogen and VEGF (B) 
for PLMA100 10% and 15% (w/v). 
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Conclusions 
 
PRP and PL are attractive sources of GFs that have been widely studied for TE 
applications. Previous studies found in the literature concerning the use of hydrogels based 
on PRP, mostly report the activation with bovine thrombin and crosslinking with calcium. 
Despite the potential of those systems, the limited mechanical properties, and low stability 
in vitro results in an ineffective strategy. Herein we reported for the first time, a direct 
modification of PL proteins with a photoresponsive group. Such modification allow the 
production of PL derived photopolymerized hydrogels with tunable mechanical properties. 
The PLMA based hydrogels here proposed not only have increased mechanical properties 
but also higher stability in vitro when compared to PRP/PL based reported materials. PLMA 
based hydrogels support the growth of encapsulated cells. Our results suggest that such type 
of gels may be an alternative to collagen and Matrigel, the gold standards to provide 3D cell 
cultures for a wide range of cell types. A foremost advantage of PLMA based gels is their 
human origin, following the current animal-free approaches and autologous strategies for 
cell culture and biomedical applications. The bioactivity of the modified proteins should be 
understood and will be performed in future studies. Recognizing the unprecedented potential 
of the PLMA gels to support 3D cell culture, we hypothesize that PLMA based gels may be 
used as cell culture platforms avoiding the use of animal derived supplements.  
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Conclusions and future perspectives 
Regenerative medicine and tissue engineering (TE) are emerging areas aiming to 
develop new strategies for tissue healing and regenerative process. Platelets are a natural 
reservoir of GFs and are activated at sites of tissue injury, where they promote tissue repair, 
including revascularization. PRP injections have become popular, particularly with 
treatments for musculoskeletal injuries. In addition, PRP and its derivatives like platelet 
lysates (PL) have recently emerged as promising candidates for replacing animal serum in 
cell culture.   
PRP also contains extracellular matrix (ECM) precursors, like fibrinogen, offering a 
fully human option to engineer a biodegradable scaffold for cell encapsulation and 3D cell 
culture. In fact, PRP based gels have been widely explored as implantable materials for tissue 
regeneration, still these materials have poor mechanical properties and poor stability in vitro 
and in vivo. In this contribution, the advances in the applications of plasma derived materials 
are critically reviewed and their shortcomings are pointed out in chapter 3 of this thesis. In 
addition, we highlight the limitations of the currently PRP based hydrogels as 3D matrices 
for cell culture.  
The major goal of this thesis was the development of a novel process for making a 
crosslinked blood plasma derived hydrogel, which shows increased stability compared to 
PRP based hydrogels of the art. In chapter 4 of this thesis the development and 
characterization of PRP/PL based hydrogel which are bioactive and have tunable mechanical 
properties are reported. More particularly, the present work relates to the modification of PL 
proteins with a methacryloyl group (PLMA) that allows further chemical crosslinking upon 
UV light. PLMA hydrogels here proposed have increased mechanical properties and higher 
stability in vitro when compared to PRP/PL reported in the literature. It was here 
demonstrated that the mechanical properties and microstructure of PLMA gels can be easily 
tuned by changing PL degree of modification and material concentration. Biological studies, 
reveal that PLMA gels support cell growth for over 7 days. Remarkably, since day 1 the 
encapsulated human cells could also perform important biological processes such as growth 
and migration. The sustained release of proteins and growth factors was also observed. 
Future studies will include the culture of human derived cells within the PLMA gels without 
animal serum as supplement. A main objective of the strategy here proposed it is the 
exclusion of animal derived components in the in vitro assays to reduce the potential 
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contamination problems. The final goal of this project is the use of complete autologous 
materials and cells from a patient, this open up new possibilities for personalized medicine 
and thus targeted therapeutic approaches. 
This is the first study to demonstrate that chemical modification of proteins from PL, 
can be used to fabricate customizable hydrogels for 3D cell culture. Results shown that 
PLMA hydrogels provide the necessary structural and biochemical support for cell growth, 
and particularly suitable for tissue engineering or development of microtissues for drug 
screening. 
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PLMA100 
Names Sequence Modifications dMass 
Serum albumin 
AFKAWAVAR Methacrylic anhydride(K)@3 -0,0053044 
FKDLGEENFK Methacrylic anhydride(K)@2 0,00236207 
KQTALVELVK Methacrylic anhydride(K)@1 -0,0121997 
KYLYEIAR Methacrylic anhydride(K)@1 -0,00769923 
LAKTYETTLEK Methacrylic anhydride(K)@3 -0,00462136 
QIKKQTALVELVK Methacrylic anhydride(K)@4 0,022857601 
YTKKVPQVSTPTLVEVSR Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@4 -0,001706 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(Q)@4; Methacrylic anhydride(K)@6 -0,0118432 
QTALVELVKHKPK Methacrylic anhydride(K)@9; Methacrylic anhydride(K)@11 0,00915571 
ADDKETCFAEEGKK Methacrylic anhydride(K)@13 0,0195789 
ADDKETCFAEEGKK Methacrylic anhydride(K)@14 0,0195789 
ADDKETCFAEEGKK Methacrylic anhydride@N-term -0,0115307 
AEFAEVSK Methacrylic anhydride@N-term -0,01199 
AVMDDFAAFVEK Methacrylic anhydride@N-term -0,0126826 
CCKADDKETCFAEEGKK Methacrylic anhydride(K)@3 -0,028849101 
DAHKSEVAHR Methacrylic anhydride@N-term; Methacrylic anhydride(K)@4 8,74E-05 
DDNPNLPR Methacrylic anhydride@N-term -0,0175192 
EQLKAVMDDFAAFVEK Methacrylic anhydride(K)@4 0,00211765 
FDEFKPLVEEPQNLIK Methacrylic anhydride(K)@5 0,0269637 
FKAWAVAR Methacrylic anhydride(K)@2 -0,0150526 
FKDLGEENFK Methacrylic anhydride(K)@2 0,00236207 
FPKAEFAEVSK Methacrylic anhydride(K)@3 -0,0044001 
FQNALLVR Methacrylic anhydride(Q)@2 -0,0132629 
FQNALLVR Methacrylic anhydride@N-term -0,0123888 
FYAPELLFFAKR Methacrylic anhydride(R)@12 0,0245356 
HPYFYAPELLFFAK Methacrylic anhydride@N-term -0,0144739 
HPYFYAPELLFFAK Methacrylic anhydride(H)@1 -0,0144739 
HPYFYAPELLFFAKR Methacrylic anhydride(R)@15 0,0223991 
KQTALVELVK Methacrylic anhydride(K)@1 -0,0121997 
KQTALVELVK Methacrylic anhydride(Q)@2 0,0115714 
KVPQVSTPTLVEVSR Methacrylic anhydride(K)@1 -0,0139793 
KVPQVSTPTLVEVSR Methacrylic anhydride(Q)@4 -0,049004599 
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KVPQVSTPTLVEVSR Methacrylic anhydride(K)@1; Methacrylic anhydride(Q)@4 0,000517534 
KYLYEIAR Methacrylic anhydride(K)@1 -0,00824722 
LAKTYETTLEK Methacrylic anhydride(K)@3 -0,00462136 
LAKTYETTLEK Methacrylic anhydride@N-term 0,020749699 
LCTVATLR Methacrylic anhydride@N-term -0,0128611 
LDELRDEGK Methacrylic anhydride@N-term 0,00616255 
LDELRDEGKASSAK Methacrylic anhydride(R)@5; Methacrylic anhydride(K)@9 0,00113728 
LDELRDEGKASSAK Methacrylic anhydride(R)@5 0,0274675 
LDELRDEGKASSAKQR Methacrylic anhydride(K)@9; Methacrylic anhydride(K)@14 0,0022549 
LDELRDEGKASSAKQR Methacrylic anhydride(K)@14 -0,021606401 
LDELRDEGKASSAKQR Methacrylic anhydride(K)@14; Methacrylic anhydride(Q)@15 0,00276091 
LVAASQAALGL Methacrylic anhydride@N-term -0,0116827 
LVNEVTEFAK Methacrylic anhydride@N-term -0,011087 
LVRPEVDVMCTAFHDNEETFLKK Methacrylic anhydride(K)@22 -0,017450901 
QIKKQTALVELVK Methacrylic anhydride(Q)@1; Methacrylic anhydride(K)@4 0,000304357 
QIKKQTALVELVK Methacrylic anhydride(K)@4 0,021931199 
QNCELFEQLGEYK Methacrylic anhydride(Q)@1 -0,0132572 
QNCELFEQLGEYK Methacrylic anhydride@N-term -0,0132572 
QNCELFEQLGEYK Methacrylic anhydride(N)@2 -0,0123137 
RHPDYSVVLLLR Methacrylic anhydride(H)@2 0,0065927 
RYKAAFTECCQAADK Methacrylic anhydride(R)@1 -0,00166275 
TKCCTESLVNR Methacrylic anhydride(K)@2 0,021412401 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride@N-term; Methacrylic anhydride(K)@2; Methacrylic anhydride(K)@6 -0,0118432 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(Q)@4; Methacrylic anhydride(K)@6 -0,0123628 
VFDEFKPLVEEPQNLIK Methacrylic anhydride@N-term -0,016495099 
VGSKCCKHPEAK Methacrylic anhydride(K)@7 -0,0109704 
VGSKCCKHPEAK Methacrylic anhydride(K)@4 -0,0109704 
VNEVTEFAK Methacrylic anhydride(N)@2 0,0131231 
VPQVSTPTLVEVSR Methacrylic anhydride@N-term; Methacrylic anhydride(Q)@3 0,0154781 
VTKCCTESLVNR Methacrylic anhydride(K)@3 -0,0113639 
YKAAFTECCQAADK Methacrylic anhydride@N-term 0,027179301 
YTKKVPQVSTPTLVEVSR Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@4 -0,001706 
Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=3 
KASYLDCIR Methacrylic anhydride(K)@1 -0,00667122 
CLKDGAGDVAFVK Methacrylic anhydride(K)@3 -0,024202799 
KCSTSSLLEACTFR Methacrylic anhydride(K)@1 -0,00331561 
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Apolipoprotein A-I 
QKVEPLRAELQEGAR Methacrylic anhydride(K)@2 -0,000459271 
KWQEEMELYR Methacrylic anhydride(W)@2 0,028870599 
Immunoglobulin gamma-1 heavy 
chain 
GPSVFPLAPSSKSTSGGTAALGCLVK Methacrylic anhydride(K)@12 -0,00536033 
FNWYVDGVEVHNAK Methacrylic anhydride@N-term -0,016043199 
FNWYVDGVEVHNAK Methacrylic anhydride(W)@3 -0,016043199 
Immunoglobulin heavy constant 
alpha 1 
DASGVTFTWTPSSGKSAVQGPPER Methacrylic anhydride(K)@15 -0,00264049 
VAAEDWKK Methacrylic anhydride(K)@7 -0,0252777 
WLQGSQELPR Methacrylic anhydride@N-term -0,0100065 
WLQGSQELPR Methacrylic anhydride(W)@1 -0,0100065 
Immunoglobulin heavy constant 
gamma 2 
FNWYVDGVEVHNAK Methacrylic anhydride(W)@3 -0,016043199 
FNWYVDGVEVHNAK Methacrylic anhydride@N-term -0,016043199 
Immunoglobulin lambda constant 
2 
ADSSPVKAGVETTTPSK Methacrylic anhydride(K)@7 -0,00450191 
YAASSYLSLTPEQWKSHR Methacrylic anhydride(K)@15 -0,0234867 
Immunoglobulin alpha-2 heavy 
chain 
TTVTVSSASPTSPK Methacrylic anhydride@N-term 0,025227699 
VAAEDWKK Methacrylic anhydride(K)@7 -0,0252777 
WLQGSQELPR Methacrylic anhydride(W)@1 -0,0100065 
WLQGSQELPR Methacrylic anhydride@N-term -0,0100065 
Immunoglobulin lambda-1 light 
chain; Immunoglobulin lambda-
like polypeptide 5 
YAASSYLSLTPEQWKSHR Methacrylic anhydride(K)@15 -0,0234867 
Immunoglobulin heavy constant 
gamma 4 
FNWYVDGVEVHNAK Methacrylic anhydride(W)@3 -0,016043199 
FNWYVDGVEVHNAK Methacrylic anhydride@N-term -0,016043199 
Glutamate receptor ionotropic, 
NMDA 1 
QNVSLSILK Methacrylic anhydride(K)@9 -0,0131732 
Purine nucleoside phosphorylase VIMDYESLEK Methacrylic anhydride(K)@10 -0,0130048 
 
Table 1. MA modified peptides and correlated proteins for PLMA100 modification. 
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PLMA300 
Names Sequence Modifications dMass 
Serum albumin 
AACLLPKLDELR Methacrylic anhydride(K)@7 -0,00233865 
KYLYEIAR Methacrylic anhydride(K)@1 -0,00370284 
LDELRDEGKASSAKQR Methacrylic anhydride(K)@9; Methacrylic anhydride(K)@14 0,00298238 
LECADDRADLAKYICENQDSISSK Methacrylic anhydride(K)@12 -0,0217715 
LKCASLQKFGER Methacrylic anhydride(K)@2; Methacrylic anhydride(K)@8 -0,00306525 
LVNEVTEFAKTCVADESAENCDK Methacrylic anhydride(K)@10 -0,0105955 
NECFLQHKDDNPNLPR Methacrylic anhydride(K)@8 0,00180468 
SLHTLFGDKLCTVATLR Methacrylic anhydride(K)@9 -0,0040148 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(Q)@4; Methacrylic anhydride(K)@6 -0,00493928 
VGSKCCKHPEAK Methacrylic anhydride(K)@7 -0,025557499 
VTKCCTESLVNR Methacrylic anhydride(K)@3 -0,00730587 
YKAAFTECCQAADKAACLLPK Methacrylic anhydride(K)@2; Methacrylic anhydride(K)@14 -0,0156286 
ETYGEMADCCAKQEPERNECFLQHKDDNPNLPR Methacrylic anhydride(K)@12 0,0286284 
CCKADDKETCFAEEGKK Methacrylic anhydride(K)@3 -0,0225899 
YTKKVPQVSTPTLVEVSR Methacrylic anhydride(K)@3 0,0223688 
ATKEQLK Methacrylic anhydride(K)@3 -0,00475801 
LAKTYETTLEKCCAAADPHECYAK Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@11 0,00145459 
QIKKQTALVELVK Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@4 -0,00038923 
PKATKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(K)@5; Methacrylic anhydride(K)@9 -0,0348919 
FPKAEFAEVSKLVTDLTK Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@11 0,000838106 
FYAPELLFFAKR Methacrylic anhydride(K)@11 -0,023745099 
DHVKLVNEVTEFAK Methacrylic anhydride(K)@4 0,0264995 
KEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@5 0,000375254 
ADDKETCFAEEGK Methacrylic anhydride(K)@4 -0,0033294 
ADDKETCFAEEGKK Methacrylic anhydride(K)@14 -0,0145434 
ADDKETCFAEEGKK Methacrylic anhydride(K)@13 -0,0145434 
AEFAEVSK Methacrylic anhydride@N-term -0,0124118 
AEFAEVSKLVTDLTK Methacrylic anhydride(K)@8 -0,0150789 
AFKAWAVAR Methacrylic anhydride(K)@3 -0,00939401 
ATKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@3 -0,00434444 
ATKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@7 -0,00434444 
ATKEQLKAVMDDFAAFVEK Methacrylic anhydride@N-term; Methacrylic anhydride(K)@3 -0,000122901 
ATKEQLKAVMDDFAAFVEK Methacrylic anhydride@N-term; Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@7 -0,0088598 
ATKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@7 0,00994787 
CCKADDKETCFAEEGKK Methacrylic anhydride(K)@3 -0,026782401 
DAHKSEVAHR Methacrylic anhydride(K)@4 -0,0268817 
DAHKSEVAHR Methacrylic anhydride@N-term; Methacrylic anhydride(K)@4 -0,0338878 
DAHKSEVAHR Methacrylic anhydride(H)@3; Methacrylic anhydride(K)@4 -0,0338878 
DDKETCFAEEGKK Methacrylic anhydride(K)@3 0,0292862 
DDNPNLPR Methacrylic anhydride@N-term -0,0147698 
DVCKNYAEAK Methacrylic anhydride(K)@4 -0,00347931 
EFNAETFTFHADICTLSEKER Methacrylic anhydride(R)@21 0,026110001 
EFNAETFTFHADICTLSEKER Methacrylic anhydride(K)@19 -0,0147899 
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EQLKAVMDDFAAFVEK Methacrylic anhydride(K)@4 0,00153408 
EQLKAVMDDFAAFVEK Methacrylic anhydride(Q)@2 0,024809999 
FKAWAVAR Methacrylic anhydride(K)@2 -0,0136292 
FKDLGEENFK Methacrylic anhydride(K)@2 -0,00858875 
FKDLGEENFK Methacrylic anhydride@N-term 0,0229425 
FPKAEFAEVSK Methacrylic anhydride(K)@3 -0,0064321 
FPKAEFAEVSK Methacrylic anhydride@N-term; Methacrylic anhydride(K)@3 0,00146627 
FQNALLVR Methacrylic anhydride@N-term -0,0133743 
FQNALLVR Methacrylic anhydride(Q)@2 -0,0146548 
FYAPELLFFAKR Methacrylic anhydride(K)@11 -0,0170558 
HPDYSVVLLLR Methacrylic anhydride(H)@1 -0,0114803 
HPDYSVVLLLR Methacrylic anhydride@N-term -0,0114803 
HPYFYAPELLFFAK Methacrylic anhydride(H)@1 -0,0117885 
HPYFYAPELLFFAK Methacrylic anhydride@N-term -0,0117885 
HPYFYAPELLFFAK Methacrylic anhydride(H)@1 0,0227591 
HPYFYAPELLFFAKR Methacrylic anhydride(R)@15 0,025612701 
KEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@1 0,000375254 
KEQLKAVMDDFAAFVEK Methacrylic anhydride(Q)@3 -0,000252954 
KEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@5 0,00656782 
KQTALVELVK Methacrylic anhydride(Q)@2 -0,0120111 
KQTALVELVK Methacrylic anhydride(K)@1 -0,0126101 
KQTALVELVK Methacrylic anhydride(K)@1; Methacrylic anhydride(Q)@2 -0,0358514 
KVPQVSTPTLVEVSR Methacrylic anhydride(K)@1 -0,0146041 
KVPQVSTPTLVEVSR Methacrylic anhydride(Q)@4 -0,0146041 
KVPQVSTPTLVEVSR Methacrylic anhydride(K)@1; Methacrylic anhydride(Q)@4 -0,00249775 
KYLYEIAR Methacrylic anhydride(K)@1 -9,45E-05 
LAKTYETTLEK Methacrylic anhydride(K)@3 -0,0135266 
LAKTYETTLEKCCAAADPHECYAK Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@11 0,00145459 
LCTVATLR Methacrylic anhydride@N-term -0,0147281 
LDELRDEGK Methacrylic anhydride@N-term 0,00400725 
LDELRDEGKASSAK Methacrylic anhydride(K)@14 -0,0157097 
LDELRDEGKASSAK Methacrylic anhydride(K)@9 -0,0157097 
LDELRDEGKASSAK Methacrylic anhydride(R)@5 0,020675801 
LDELRDEGKASSAKQR Methacrylic anhydride(K)@9; Methacrylic anhydride(K)@14 0,00351159 
LECADDRADLAKYICENQDSISSK Methacrylic anhydride(K)@12 -0,0217715 
LVAASQAALGL Methacrylic anhydride@N-term -0,01296 
LVNEVTEFAK Methacrylic anhydride@N-term -0,0111327 
LVNEVTEFAKTCVADESAENCDK Methacrylic anhydride(K)@10 -0,0105955 
LVRPEVDVMCTAFHDNEETFLKK Methacrylic anhydride(K)@22 -0,023963399 
NECFLQHKDDNPNLPR Methacrylic anhydride(Q)@6 0,0254297 
NECFLQHKDDNPNLPR Methacrylic anhydride(H)@7 0,0254297 
NECFLQHKDDNPNLPR Methacrylic anhydride(K)@8 0,00197763 
QIKKQTALVELVK Methacrylic anhydride(Q)@5 -0,0066451 
QIKKQTALVELVK Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@4 -0,038372699 
QIKKQTALVELVK Methacrylic anhydride(K)@4 0,023495 
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QIKKQTALVELVK Methacrylic anhydride(K)@3 0,023495 
QNCELFEQLGEYK Methacrylic anhydride(Q)@1 -0,00738804 
QNCELFEQLGEYK Methacrylic anhydride@N-term -0,00738804 
QNCELFEQLGEYK Methacrylic anhydride(N)@2 -0,0126843 
QNCELFEQLGEYKFQNALLVR Methacrylic anhydride(K)@13 -0,00931356 
QNCELFEQLGEYKFQNALLVR Methacrylic anhydride(Q)@15 0,0120424 
QNCELFEQLGEYKFQNALLVR Methacrylic anhydride(K)@13; Methacrylic anhydride(Q)@15 -0,000807693 
QNCELFEQLGEYKFQNALLVR Methacrylic anhydride(Q)@8 0,023444301 
RAFKAWAVAR Methacrylic anhydride(K)@4 -0,0103486 
RHPDYSVVLLLR Methacrylic anhydride(H)@2 -0,019065799 
RHPDYSVVLLLR Methacrylic anhydride@N-term -0,0134026 
RHPDYSVVLLLR Methacrylic anhydride(R)@1 -0,0134026 
RHPDYSVVLLLR Methacrylic anhydride(H)@2 -0,0165489 
RYKAAFTECCQAADK Methacrylic anhydride(K)@3 -0,0102994 
SLHTLFGDKLCTVATLR Methacrylic anhydride(K)@9 -0,0040148 
SLHTLFGDKLCTVATLR Methacrylic anhydride(H)@3; Methacrylic anhydride(K)@9 0,0080417 
SLHTLFGDKLCTVATLR Methacrylic anhydride@N-term; Methacrylic anhydride(H)@3 0,00659075 
SLHTLFGDKLCTVATLR Methacrylic anhydride@N-term; Methacrylic anhydride(K)@9 -0,00152457 
SLHTLFGDKLCTVATLR Methacrylic anhydride(H)@3 0,0125291 
SLHTLFGDKLCTVATLR Methacrylic anhydride(H)@3 0,022907101 
TCVADESAENCDK Methacrylic anhydride(K)@13 0,0128826 
TECCHGDLLECADDRADLAK Methacrylic anhydride@N-term; Methacrylic anhydride(H)@5 0,010497 
TKCCTESLVNR Methacrylic anhydride(K)@2 0,022470299 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride@N-term; Methacrylic anhydride(K)@2; Methacrylic anhydride(K)@6 -0,0146839 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(Q)@4; Methacrylic anhydride(K)@6 -0,0146839 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2 -0,00918596 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(K)@6 0,00451451 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(K)@2; Methacrylic anhydride(Q)@4 0,00147543 
TKEQLKAVMDDFAAFVEK Methacrylic anhydride(Q)@4 0,00272648 
VFDEFKPLVEEPQNLIK Methacrylic anhydride@N-term -0,0116931 
VFDEFKPLVEEPQNLIK Methacrylic anhydride(K)@6 -0,018092999 
VFDEFKPLVEEPQNLIKQNCELFEQLGEYK Methacrylic anhydride(K)@17 0,020436101 
VGSKCCKHPEAK Methacrylic anhydride(K)@4 -0,025557499 
VGSKCCKHPEAK Methacrylic anhydride(K)@7 -0,0210864 
VNEVTEFAK Methacrylic anhydride(N)@2 0,0136247 
VPQVSTPTLVEVSR Methacrylic anhydride@N-term; Methacrylic anhydride(Q)@3 0,00652401 
VTKCCTESLVNR Methacrylic anhydride(K)@3 0,00147493 
YICENQDSISSKLK Methacrylic anhydride(K)@14 0,0205606 
YICENQDSISSKLK Methacrylic anhydride(K)@12 0,0205606 
YKAAFTECCQAADK Methacrylic anhydride@N-term 0,0197674 
YKAAFTECCQAADK Methacrylic anhydride(K)@2 0,00811773 
YTKKVPQVSTPTLVEVSR Methacrylic anhydride(K)@3 0,00508104 
YTKKVPQVSTPTLVEVSR Methacrylic anhydride(K)@4 0,00508104 
YTKKVPQVSTPTLVEVSR Methacrylic anhydride(K)@3; Methacrylic anhydride(K)@4 -0,00749501 
Complement C3 EPGQDLVVLPLSITTDFIPSFR Methacrylic anhydride(Q)@4 -0,0181063 
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IFTVNHKLLPVGR Methacrylic anhydride(K)@7 -0,00717962 
QGALELIKK Methacrylic anhydride(K)@8 0,0243588 
QGALELIKK Methacrylic anhydride(K)@9 0,0243588 
Serotransferrin 
CLKDGAGDVAFVK Methacrylic anhydride(K)@3 -0,0222151 
KSASDLTWDNLK Methacrylic anhydride(K)@1 -0,0129697 
NLNEKDYELLCLDGTR Methacrylic anhydride(K)@5 0,00147754 
NPDPWAKNLNEKDYELLCLDGTR Methacrylic anhydride(K)@12 -0,0145057 
SVIPSDGPSVACVKK Methacrylic anhydride(K)@15 -0,0109093 
KSASDLTWDNLKGK Methacrylic anhydride(K)@12 0,0128116 
CLKDGAGDVAFVK Methacrylic anhydride(K)@3 -0,0035064 
GWNIPIGLLYCDLPEPR Methacrylic anhydride(W)@2; Methacrylic anhydride(N)@3 -0,0236942 
KASYLDCIR Methacrylic anhydride(K)@1 -0,0077725 
KCSTSSLLEACTFR Methacrylic anhydride(K)@1 -0,0110026 
KDSGFQMNQLR Methacrylic anhydride(K)@1 0,00363786 
MDAKMYLGYEYVTAIR Methacrylic anhydride(K)@4 0,00383966 
NPDPWAKNLNEKDYELLCLDGTR Methacrylic anhydride(K)@7 -0,0145057 
SASDLTWDNLKGK Methacrylic anhydride(K)@11 -0,023888201 
SKEFQLFSSPHGK Methacrylic anhydride(K)@2 0,0088012 
SVIPSDGPSVACVKK Methacrylic anhydride(K)@14 -0,0215207 
Alpha-2-macroglobulin 
GHFSISIPVKSDIAPVAR Methacrylic anhydride(K)@10 -0,017948 
GVPIPNKVIFIR Methacrylic anhydride(K)@7 -0,00469111 
Alpha-1-antitrypsin 
LSITGTYDLKSVLGQLGITK Methacrylic anhydride(K)@10 0,00175891 
GTQGKIVDLVK Methacrylic anhydride(K)@5 -0,0071879 
LVDKFLEDVKK Methacrylic anhydride(K)@4 0,00242497 
LVDKFLEDVKK Methacrylic anhydride(K)@10 -0,0221914 
SVLGQLGITKVFSNGADLSGVTEEAPLK Methacrylic anhydride(K)@10 -0,0122591 
Haptoglobin 
FTDHLKYVMLPVADQDQCIR Methacrylic anhydride(K)@6 -0,00149392 
HYEGSTVPEKK Methacrylic anhydride(K)@10 -0,023800701 
DIAPTLTLYVGKK Methacrylic anhydride(K)@12 -0,0261031 
DIAPTLTLYVGKK Methacrylic anhydride(K)@13 0,0233745 
HYEGSTVPEKK Methacrylic anhydride(K)@11 0,0238182 
HYEGSTVPEKK Methacrylic anhydride(K)@10 -0,021717001 
ILGGHLDAKGSFPWQAK Methacrylic anhydride(K)@9 -0,010681 
Apolipoprotein A-I 
VKDLATVYVDVLK Methacrylic anhydride(K)@2 -0,00621585 
LAARLEALKENGGAR Methacrylic anhydride(K)@9 -0,00251401 
AKPALEDLR Methacrylic anhydride@N-term 0,026486499 
AKVQPYLDDFQKK Methacrylic anhydride@N-term 0,023417801 
KWQEEMELYR Methacrylic anhydride(W)@2 0,025477899 
KWQEEMELYR Methacrylic anhydride(K)@1 8,98E-05 
LEALKENGGAR Methacrylic anhydride(K)@5 -0,026768699 
LEALKENGGAR Methacrylic anhydride(R)@11 -0,026768699 
VKDLATVYVDVLK Methacrylic anhydride(K)@2 -0,00422069 
Complement C4-B DHAVDLIQKGYMR Methacrylic anhydride(K)@9 -0,00509481 
Table 2. MA modified peptides and correlated proteins for PLMA300 modification. 
